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Multivariate failure time data arise when two or more distinct failures are
recorded on an individual. We consider competing and semi-competing risks
data, involving failures of different types. The latter occurs when a terminal
event censors a non-terminal event but not vice-versa. The proportional haz-
ards model is commonly used to examine relative risk. As a viable alternative
to the proportional hazards model, the additive risks model examines excess
risk and provides a flexible tool of modeling multivariate failure time data. We
propose a class of additive risk models for the analysis of competing risks and
semi-competing risks data. In all cases, we investigate the theoretical and nu-
merical properties of the estimators. Simulations were conducted to assess the
performance of the proposed models.
First, we consider the additive risk approach for competing risks data by mod-
eling both the cause-specific and subdistribution hazards. Simulation results
show that estimation is fairly accurate with little bias. We also apply our
method to a real dataset on prostate cancer and analyse treatment effects of
high-dose versus low-dose diethylstilbestrol (DES) on the outcome of interest
(cancer death) and competing risks endpoints (cardiovascular death and other
causes of death), while accounting for other covariates. Results indicate in-
creased survival chances from cancer death for patients receiving high-dose DES
in both cause-specific hazard and subdistribution hazard models.
vii
Secondly, we suggest an additive risk frailty model for semi-competing risks
data. Frailties are used to model the dependence between the terminal and
non-terminal events and covariate effects are examined by excess risk given the
frailty. Splines are used to model the conditional baseline hazard nonparamet-
rically. Simulations indicate that estimates have about 10% bias for moderate
sample sizes. Application to a randomized clinical trial on nasopharyngeal can-
cer shows the practical utility of the model. The incorporation of the depen-
dence structure reveals that patients in the chemotherapy group have increased
chances of disease-free survival as compared to the radiotherapy group. Our
results show that the chemotherapy group actually has increased risk of death
without relapse and a reduced risk of death after relapse.
Finally, the extension to the more general additive-multiplicative frailty risk
model for semi-competing risks data is discussed, with a similar splines approx-
imation method for the baseline hazards. Simulations indicate estimation has
little bias for the multiplicative component, while the estimates of the additive
components had biases of at most 0.1. We re-examine the nasopharyngeal cancer
dataset using this additive-multiplicative model under the reduced compartment
model, with the treatment variable as a multiplicative effect and adjusting for
nodal status and TNM staging as additive effects. Results show the significance
of all three variables. Patients in the chemoradiotherapy group have a lower risk
of both relapse and death as compared to patients in the radiotherapy group,
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1Chapter 1
Introduction
Survival analysis is the analysis of data where the response is the time until an
event of interest occurs. In the case of univariate failure time data, research
on modelling its underlying distribution and its dependence on explanatory
variables are now well-established. However, additional problems arise when
we deal with multivariate failure times and types. Multivariate failure time
data arise when two or more distinct failures are recorded on an individual.
These failures could be recurrent failures or distinct failures of different types
(Kalbfleisch and Prentice, 2002).
Recurrent failures are observed in diverse settings, for instance, repeated episo-
des of infection, a sequence of asthmatic attacks, or epileptic seizures. Distinct
failures of multiple types occur when the failures are of an entirely different
nature, such as local or distant recurrences in cancer studies. In the context
of competing risks, the failures are usually of different types, and the subject
may fail from one of these distinct causes. (Tai et al., 2008). For example, in
a randomized clinical trial of patients with Stage III and IV nasopharyngeal
cancer, the competing failures of interest were distant metastasis, local relapse,
and neck relapses (Wee et al., 2005). Similarly, in a clinical trial investigating
2whether antiretroviral treatment delays the development of individual AIDS
events, the different events of interest included oesophageal candidiasis, Kaposi
sarcoma, pneumocystis carinii pneumonia, disseminated Mycobacterium avium
intercellulare, cytomegalovirus, cryptosporidiosis, and cerebral toxoplasmosis
(Delta Coordinating Committee, 1996).
This dissertation deals with multivariate failure time data of the latter type. It
is biologically plausible that the failure times of these distinct failure types may
be strongly correlated when observed in the same individual. Such failure time
data can be considered clustered. In univariate failure time analysis, clustering
may also arise when subjects are grouped based on common dependencies within
groups. For example, in clustered randomized clinical trials of a general practice
(primary care provider), all the patients in a general practice will be allocated
to the same intervention, with the general practice forming a cluster. Similarly,
in cohort studies on family members in genetic epidemiology, the family unit
forms the cluster. In either case, members of a cluster will be more like one
another than they are like members of other clusters. We need to take this into
account in the analysis and design of the study. Ignoring clustering may result
in misleading conclusions.
A particular case of multivariate failure time data is that of bivariate survival
data. Here, there are two non-negative survival times, T1 and T2, that are corre-
lated and have a particular joint survival function that expresses the dependence
between the two times. For example, in the Diabetic Retinopathy Study (Hus-
ter et al., 1989) the outcome of interest was the time to blindness in each eye of
197 patients with diabetic retinopathy. For each patient, one eye was randomly
selected for treatment and the other eye was observed without treatment.
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A special case of bivariate failure time data is the so-called semi-competing risks
data (Fine et al., 2001), where each subject may experience either a terminal
event or a non-terminal event. The terminal event censors the non-terminal
event, but not vice versa. In a randomised clinical trial conducted in Singapore
comparing two treatments on nasopharyngeal cancer (Wee et al., 2005), patients
may experience the terminal event - death, or the non-terminal event - relapse of
cancer at local or distant sites. It is plausible that the times to death and relapse
are highly correlated. The dependence between the times to terminal event and
non-terminal event, as well as the asymmetric structure of semi-competing risks
data, have created challenges for statistical analysis of such data, especially for
covariance analysis.
1.1 Frailty Models
One way of accounting for the dependence in multivariate failure time data is the
use of frailties. Frailty models attempt to characterize the association between
failure times through the use of a common unobserved random variable, known
as the frailty. The frailty model has been extensively used for univariate failure
time data, especially for clustered data where subjects experience a common
dependence within a particular group. Under the structure of a frailty model
for bivariate survival data, conditional on the frailty, T1 and T2 are considered
independent.
Covariate analysis is often implemented through the use of the Cox proportional
hazards model. Conditional on the frailty terms, the marginal hazard functions
for T1 and T2 follow independent proportional hazards models. Let tij, (i =
1, . . . , n and j = 1, 2), represent the failure time of the i-th individual for for
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the j-th type. Thus, the conditional hazard function is given as
λ(tij|γi, Zij) = γiλ0(tij)eβTZij ,
where Zij is the vector of covariates, β is the vector of regression coefficients,
λ0(·) is the unspecified baseline hazard function and {γ1, . . . , γn} are the inde-
pendent and identically distributed frailties.
Just as there are different kinds of copulas that one can use, there are also
various distributions that the frailty variable can follow. A convenient and pop-
ular choice is the gamma distribution (Clayton and Cuzick, 1985; Nielsen et al.,
1992). Hougaard (1984, 1986a,b) considers the inverse Gaussian and positive
stable distributions, and a three-parameter family of distributions, while Yau
(2001) suggests that the frailties follow a lognormal distribution. Hougaard
(1986b) makes a strong case for the positive stable distribution. Firstly, he
points out a shortcoming of the gamma frailty distribution in that the de-
pendence parameter and regression parameters are confounded and the joint
distribution can be identified from the marginal distribution. This problem is
present for any distribution with a finite mean. Secondly, the positive stable
distribution has an added advantage that it preserves the proportionality of the
hazards to the marginal distribution.
EM algorithms and maximum likelihood estimation (MLE) are often suggested
as the method to estimate the frailty parameter, as well as regression coefficients.
Since the frailty term is a latent variable, it makes sense to estimate these terms
in the E-step, then use these estimators in the maximization of the likelihood
in the M-step. Clayton and Cuzick (1985) use an EM-type algorithm with
pseudo-observations of marginal distribution rank score orders to estimate the
1.2 Additive Risk Models and Clustered Data 5
regression and association parameters. Nielsen et al. (1992) also use the EM
algorithm to estimate the regression and association parameters, as well as the
unspecified baseline hazard for the proportional hazards model with a gamma
frailty. Lam and Kuk (1997) propose the use of the marginal likelihood to
estimate the parameters and suggest that this approach works for any frailty
distribution with explicit Laplace transform. Gorfine et al. (2006) develop a
new inference technique that can handle any parametric frailty distribution with
finite moments. The method proposed is a pseudo-likelihood method that uses
a plug-in estimator for the cumulative hazard function and avoids complicating
the iterative optimization process.
1.2 Additive Risk Models and Clustered Data
While the Cox proportional hazards model has been widely discussed and ex-
tended, there is another formulation that describes a different aspect of the
association between covariates and the failure time — the additive risk model.
The additive risk model is adopted when the absolute effects, instead of relative
effects, of predictors on the hazard function are of interest. In this way, we can
analyse excess risk, instead of relative risk.
The intuitive idea for the additive risk approach is that the background disease
incidence rate (or hazard rate) is due to the presence of general factors that are
common to all subjects. The exposure to a particular treatment or agent under
investigation causes the difference in an individual’s overall hazard rate and is
unrelated to the general factors. The differences in exposure are represented as
excess risk (Breslow and Day, 1980). In some cases, the analysis of the estimated
parameters results in the preference of excess risk measure over the relative risk
measure.
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Aalen (1980) first introduced the nonparametric version of the additive risk
model. The estimators obtained by Aalen (1980) were a generalisation of the
Nelson-Aalen (or natural) estimator and were based on least-squares type meth-
ods. Huffer and McKeague (1991) then extended the estimation to include
weighted least-squares estimators for Aalen’s additive risk model.
As mentioned earlier, the additive risk can be considered as an additive analogue
to the Cox proportional hazards model. Here, the hazard function for the i-th
individual is given as
λ(t|Zi) = λ0(t) + βTZi(t)
where Zi is the vector of covariates that are allowed to vary with time, β is
the vector of regression coefficients, and λ0(·) is the unspecified baseline haz-
ard function. Lin and Ying (1994) consider this model with time-dependent
covariates and develop a semiparametric estimating function for the regression
coefficient vector β. They first estimate the cumulative baseline hazard with
a natural estimator and use this estimator in the estimating function. The re-
sulting function mimics the martingale feature of the partial likelihood score
function under a proportional hazards model. Explicit forms for the estimates
were obtained. Under this method, the estimators converge weakly to a multi-
variate normal distribution with mean 0 and a covariance matrix that can be
consistently estimated.
Note that a limitation of the additive risk model is that it is complicated by the
constraint that the hazard function must be nonnegative (Huffer and McKeague,
1991; Lin and Ying, 1994). Thus, Lin and Ying (1994) suggest a substitution of
eβ
TZi(t) for βTZi(t). However, there is now no explicit solution to the estimating
equation and the Newton-Raphson algorithm is required. Analysis is also more
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complicated numerically and theoretically.
The estimators of Lin and Ying (1994) are used by Pipper and Martinussen
(2004) in applying the additive risk model to the clustered failure time setting
with clusters. A marginal additive hazards model like that of Lin and Ying
(1994) is suggested and the estimating function follows accordingly. Bearing
in mind that we can no longer assume independence between failure times in
clusters, working independence estimators that parallel those suggested by Lin
and Ying (1994) are obtained. It is also shown that the working independence
estimators of the regression coefficients are consistent and converge in distri-
bution to a normal vector with zero mean and the estimator of the baseline
cumulative hazard converges weakly to a Gaussian process.
Since it is of interest to estimate measures of dependence between failure times
in a cluster, Pipper and Martinussen (2004) assume an additive marginal hazard,
a parametric frailty and independence between the frailties and covariates in the
respective clusters. Frailties, indicated as γk for k = 1, . . . , K, are assumed to be
independent and identically distributed positive random variables with Laplace
transform φθ(u) = Eθ{e−uγ1}, where θ is parameter associated with the frailty
distribution. Through the use of the innovation theorem (Andersen et al., 1993),
observed intensities are obtained up to time t and again, estimating equations
are found that follow those of Lin and Ying (1994). Proper estimating equations
are obtained by first inserting natural estimators for the baseline hazard and
cumulative baseline hazard. The incorporation of the dependence through the
frailty variable results in a more efficient estimation of the regression parameters
as compared to the working independence estimators. While the choice of frailty
distribution is not specified, conditions are placed on the frailty distribution to
ensure that the Laplace transform φθ(u) behaves nicely at the boundary. Thus,
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this excludes distributions such as the positive stable distribution.
We now restrict our focus to semi-competing risks data and look at various
methods of modelling such data. It is noted that the methods discussed are
applicable to the more general cases of multivariate and clustered survival data.
1.3 Nonparametric Estimation in Semi-
Competing Risks
Semi-competing risks occur when there is a terminal failure time, T2 , and a non-
terminal failure time, T1 (Fine et al., 2001). The random variable T2 may censor
T1, but not vice-versa. This results in dependent censoring and there is possible
correlation between T1 and T2. Such data are often encountered in medical
studies. In cancer trials, when the goal is to estimate disease-free survival, the
relapse of the disease is the non-terminal event of interest. However, terminal
death from other causes censors the relapse.
Because of the asymmetric data structure, modelling can only be defined on the
upper wedge, U = {(t1, t2) : 0 < t1 ≤ t2 <∞}. Fine et al. (2001) introduced
the term “semi-competing risk” and developed a method to model the depen-
dence of the two event times. They also developed an estimator for the marginal
distribution of the non-terminal event, as it is often of scientific interest to model
its marginal distribution.
To model the dependence structure, they posited the use of the Clayton (1978)
copula. A copula is a parametric method of transforming marginal distributions
and expressing the transformed variables as a multivariate joint distribution.
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The Clayton copula is specified as
S(t1, t2) =
{
S1(t1)1−θ + S2(t2)1−θ − 1
}1/(1−θ)
,
where S(t1, t2) = P (T1 > t1, T2 > t2) is the joint survival function and S1(t1) =
P (T1 > t1) and S2(t2) = P (T2 > t2) are the marginal survival functions of T1
and T2 respectively. Clayton’s copula is an Archimedean copula with φθ(t) =
(t1−θ − 1)/(θ − 1). It is useful to note that because of the structure of semi-
competing risks data, the distribution of the terminal event, T2, can be easily
estimated using existing methods for univariate failure time data. Under the
copula model, θ is known as the association parameter. Hence, it is of interest
to estimate θ and S1.
An estimator for the association parameter is obtained from a concordance es-
timating function and is determined as the ratio of concordant to disconcordant
pairs. This is based on the idea that the cross-ratio function is equal to the
association parameter for the Clayton copula (Oakes, 1989). The cross-ratio
function is defined as the ratio of the hazard function of the conditional distri-
bution of T2, given T1 = t1, to that of T2, given T1 > t1 and can be written in
notation as
λ(t2|T1 = t1)
λ(t2|T1 > t1) . (1.1)
With regard to the estimator of S1, it is obtained through a rearrangement of
the copula distribution given earlier. Some algebra gives
S1(t) = {S2(t)1−θ − Sm(t)1−θ + 1}1/(1−θ),
where Sm(t) = P (T1 > t, T2 > t) = S(t, t) is the copula model defined at t.
Using this definition, Fine et al. (2001) suggest that the estimator of S1 can be
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found by
Sˆ1(t) = {Sˆ2(t)1−θˆ − Sˆm(t)1−θˆ + 1}1/(1−θˆ),
where Sˆ2 and Sˆm are the Kaplan-Meier nonparametric estimators for S2 and
Sm and θˆ is the estimate of θ found earlier.
Jiang et al. (2005) provides another estimator for the survival function of T1.
The estimator is based on self-consistent estimating equations and is a step
function that jumps at observed times. In contrast, Fine’s estimator jumps not
only at the observed times, but also at times outside the observed range. Thus,
in this aspect, Jiang’s estimator is an improvement and has better properties
than the one proposed by Fine et al. (2001).
Wang (2003) extends the above model to a more general class of Archimedean
copulas to model the dependency. These copulas can be written as
Cθ(u, v) = φ−1θ {φθ(u) + φθ(v)}, 1 ≥ v, u ≥ 0,
where φθ is a non-increasing convex function defined on (0,1] with φθ(1) = 0.
Wang (2003) considers two general dependence structures defined on the upper
wedge U — one based on the cross-ratio function defined earlier and the other
based on the Archimedean copula to model the joint distribution. From these
two dependence structures, Wang (2003) suggests several estimating functions
for the association parameter, θ. The variance of the estimator is complicated
and a resampling method, such as the jackknife approach, is used to obtain an
estimate of the variance.
Lakhal et al. (2008) provides a unified framework that generalizes the estima-
tion of the association parameter for the family of Archimedean copulas. They
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also use the cross-ratio function, defined in Equation (1.1), to construct an es-
timating function and show that the estimating functions provided by Fine et
al. (2001) and Wang (2003) are special cases of their function. In addition,
they present a method of estimating the survival function of T1. The copula-
graphic estimator they used was first introduced by Zheng and Klein (1995). In
the latter, they assumed that the joint distribution of the failure and censoring
times follow a known copula and derived estimating functions for the marginal
survival function. Rivest and Wells (2001) found a closed-form expression for
the survival function when the Archimedean copula is employed and this is the
estimator that Lakhal et al. (2008) used. Under the method proposed, limiting
distributions for the estimated copula parameter and survival function of T1 are
found and this is an improvement over the previous estimator.
The link between bivariate distributions generated by frailty models and Archi-
medean copulas is established by Oakes (1989). He presents a criterion based
on the cross-ratio function and demonstrates that any bivariate frailty model
leads to an Archimedean survival function, though the converse does not hold.
1.4 Regression Modelling in Semi-competing
Risks
The methods mentioned so far deal with nonparametric estimation of the sur-
vival function of T1. In addition, the copula model does not include any covari-
ates. Thus, Peng and Fine (2007) focused on regression modelling, employing
time-varying effects for the marginal survival function of T1, given by
S1(t|Z) = g{θ0(t)TZ},
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where g(·) is a known monotone function and Z and θ0(t) are (p+1)×1 vectors
of covariates and time-dependent coefficients respectively. Since in the semi-
competing risks setting, T2 censors T1, a model for the dependence structure is
required in order to estimate θ0(t). Hence, a time-independent copula function
C(u, v, w), is used and the joint survival function is given as
S(t1, t2|Z) = C{S1(t1|Z), S2(t2|Z), α0(t1, t2)}, for 0 ≤ t1 ≤ t2.
Similar to earlier definitions, S1(t1|Z) = P (T1 > t1|Z) and S2(t2|Z) = P (T2 >
t2|Z) are the marginal survival functions of T1 and T2 for a given covariate vector
Z, while α0(t1, t2) is the time-dependent association parameter. Peng and Fine
(2007) also specified that the marginal survival function of T2 to be of the same
form as S1(t1|Z), though the link function and coefficient vector need not be
the same. S2(·|Z) is specified as
S2(t|Z) = h{η0(t)TZ},
and the estimator for the coefficient vector, denoted as η̂0, can be obtained using
existing methods.
The simultaneous estimation for (α0, θ0), where α0(t) = α0(t, t) is done via
nonlinear estimating functions, which are obtained from a nonlinear binary
regression model of the covariates Z on I(min(T1, T2) > t), given that T2 > t,
where I(·) is the indicator function. These functions jointly estimate α0 and θ0,
separately at each t, adopting the “working independence” assumption across
time (Liang and Zeger, 1986). Thus, the estimators obtained, α̂0(t) and θ̂0(t),
are step functions which jump only at observed failure and censoring times.
It is also suggested that a sensitivity analysis could be carried out based on
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the proposed estimation procedure. That is, at each t, we can vary α0(t) and
estimate θ0(t) at each value of α0(t). This results in bounds on the covariate
effects at t and gives us a rough idea of how sensitive the covariate effects are
to changes in the dependence structure.
Under this structure of Peng and Fine (2007), variance estimators can be ob-
tained through the delta method. In addition, nonparametric test statistics are
constructed to test the null hypothesis of r linear combinations of α0(t) and
θ0(t). One of these statistics is motivated by the Wald test, while another is
a supremum-norm test. A graphical method of model checking is suggested in
order to test the goodness-of-fit. This involves using the idea of a P-P plot to
graph the fitted joint survival function against its nonparametric estimate, for a
given covariate value. However, formal goodness-of-fit tests are not introduced
here.
Hsieh and Wang (2008) propose a method of regression analysis for semi-
competing risks data involving discrete covariates only. Again, their methodol-
ogy assumes the family of Archimedean copulas for the dependence structure.
However, separate copula models with different association parameters are as-
sumed for different covariate groups. They suggest a two-stage inference proce-
dure, where their main focus is on the estimation of the regression covariates. In
the first stage, a modification of Wang’s (2003) approach is used to estimate the
association parameters, while the marginal distributions are estimated using the
approach suggested by Fine et al. (2001). These estimators are then plugged
into the second-stage estimating equation for the regression parameters.
While the copula model has been used widely in the area of semi-competing risks
data, there are various disadvantages to the use of this type of model. Firstly,
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the copula function requires the assumption of a marginal distribution for T1,
which presumes the existence of T1 as a latent time. This is a rather hypothetical
and unnatural concept and can be considered controversial. In addition, there
is little literature on the modelling of regression covariates, which is often of
interest in medical studies. The estimation methods proposed are also rather
complicated. In contrast, our proposed method uses the additive risk frailty
model as discussed below in Equation (1.2). It simplifies the estimation to
nonlinear least-squares and the incorporation of time-dependent covariates is
relatively simple.
So far in the literature, the modelling of semi-competing risks data employs the
use of a parametric copula model for the dependence structure. In this thesis,
we propose an alternative way of examining the possible correlation between T1
and T2 via the frailty models. The frailty approach for semi-competing risks
data has been analysed by Xu et al. (2010) and Lim (2010). Both employ
the use of proportional hazards conditional on the frailty. However, Xu et al.
(2010) used a nonparametric method to describe the baseline hazards, while
Lim (2010) assumes a parametric Weibull form. In both works, the frailty was
assumed to follow the Gamma distribution with mean 1 and variance θ.
1.5 Layout of Thesis
Before embarking on our approach for modelling semi-competing risks data, we
first examine a simpler situation. In Chapter 2, we look at the competing risks
scenario, where an individual faces possible failure from multiple causes and the
failure from one cause censors the failure from the others. Currently, there are
two ways to model competing risks, either through the cause-specific hazard or
the subdistribution hazard (Fine and Gray, 1999) and the proportional hazards
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model is used. We apply the additive risk model to both the cause-specific
hazard and the subdistribution hazard. Simulations conducted to examine the
performance of the proposed model show that the estimation works well in both
approaches. As an application, we also analyse a real dataset on prostate cancer
(Green and Byar, 1980) and examine the treatment effect on the competing risks
endpoints of cancer death, cardiovascular death and other causes of death. We
apply both the cause-specific hazards and subdistribution hazards model to the
dataset since both can provide complementary information about the data.
Next, as an alternative to the proportional hazards frailty models proposed by
Xu et al. (2010) and Lim (2010), which were described at the end of the pre-
vious section, we propose an additive risk frailty approach for the modelling
of semi-competing risks data. The random effect, or frailty, is used to model
the dependence and the additive risk model is used to incorporate covariate
effects. The nature of additive risk frailty modelling enables us to develop a
class of estimation equations which can be numerically and conveniently solved
by standard iterative least squares, or nonlinear least squares estimation. The-
oretical properties of the estimator for both the dependence parameter and the
regression coefficients can be rigorously established with their variance formula
explicitly derived and consistently estimated by the sandwich formula and plug-
in methods.
Under the additive risk frailty model, conditional on the frailty, the hazards
model is an additive one. We have 3 hazard functions for each individual —
one for time to relapse, one for time to death without relapse and one for time
to death after relapse. The set of hazard functions facing the i-th individual is
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given as
λ1(t|Ti2 ≥ t, γi,Zi) = γi(λ01(t) + βT1 Zi(t)),
λ2(t|Ti1 ≥ t, γi,Zi) = γi(λ02(t) + βT2 Zi(t)),
λ3(t|Ti1 < t, γi,Zi) = γi(λ03(t) + βT3 Zi(t)). (1.2)
These hazards can be represented in a compartment model, shown in Figure
1.1.
Figure 1.1: Compartment model for semi-competing risks. Hazard functions as
shown in Equation (1.2)
In Chapter 3, we look at the context of semi-competing risks and the model
discussed at the beginning of this section. In this thesis, for the fitting of the
baseline hazards, we use the method of B-splines (de Boor, 1978). This reduces
the estimation of parameters to a finite number. Simulations indicate that the
method works well for moderate sample sizes. In addition, consistency and
asymptotic normality can be established for the estimators of the parameters
of interest — the frailty variance and the regression coefficients. We apply
our method to a randomized clinical trial in nasopharyngeal cancer (Wee et al.,
2005) and analyse treatment effect, adjusting for nodal status and TNM staging.
Results show that the model fitting treatment and accounting for nodal status
and TNM staging gives similar results to the model fitting treatment only.
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In Chapter 4, we extend the method explored in Chapter 3 and generalise it
to the additive-multiplicative model. Under such a model, we allow some of
the covariates to have an excess risk effect and others to have a relative risk
effect. Simulations on semi-competing risks data show that estimation works
well for the reduced model (relapse-death). The nasopharyngeal cancer dataset
analysed in Chapter 3 is re-examined here with the treatment covariate having
a multiplicative effect and nodal status and TNM staging as additive effects.
With this new model, all covariates now have significant effects.
1.6 Contributions to the Medical Literature
The work arising from Chapter 2 of this thesis has been presented at a seminar
talk in the first NUS Department of Statistics and Applied Probability PhD
Students’ Conference held in 2010. Parts of Chapter 3 have been presented at
the 32nd Annual Conference of the International Society for Clinical Biostatis-
ticians (Ottawa, Canada), as well as in a poster presentation at the Second
Singapore Conference on Statistical Science (NUS, 19–20 September 2011).
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Chapter 2
Additive Risk Models for
Competing Risks Data
2.1 Introduction
Semi-competing risks data can be analysed in the competing risks setting, if we
consider time to first event. Competing risks is a special case of multivariate
failure time data and is the situation where an individual can potentially expe-
rience failure from one of several distinct causes. Under the classical competing
risks framework, the causes of failure can be terminal and absorbing and there
can be more than two causes of failure. In this chapter, we explore the mod-
elling of such data, using the additive model for two different approaches. This
model will be extended to model semi-competing risks in Chapter 3.
Competing risks are commonly observed in medical research, where subjects
can experience failure from disease processes and/or non-disease-related causes.
For instance, a multicentre randomized clinical trial conducted on bone mar-
row transplant patients records competing risks endpoints including recovery,
relapse, chronic graft versus host disease and death (Couban et al., 2002). An-
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other example is data from a randomised clinical trial comparing treatment for
patients with prostate cancer, where competing risks endpoints observed were
cancer, cardiovascular and other causes of death (Green and Byar, 1980; Kay,
1986). The occurrence of one event either precludes the occurrence of another
event under investigation or alters the probability of occurrence of other events
(Gooley et al., 1999). It is easy to see that there is dependence between the
time to an event and the censoring mechanism.
Existing literature models competing risks data using two methods — the cause-
specific hazard and the subdistribution hazard. We next look at these two ap-
proaches in Sections 2.1.1 and 2.1.2 respectively.
2.1.1 Cause-Specific Hazard
The cause-specific hazard is observed when we consider competing risks as latent
(unobserved) failure times. We define the multivariate survival function as
S(t1, t2, . . . , tK |Z) = P (T1 > t1, T2 > t2, . . . , TK > tK |Z),
where T1, . . . , TK are potential, unobserved event times for each ofK event types
and Z is the covariate vector. Under the competing risks scenario, only one event
is observed, since the occurrence of this event will preclude the occurrence of
other events, that is, T = min{T1, T2, . . . , TK}. The event variable, , then
takes on values 0, 1, 2, . . . , K, where 0 means the observation is censored and a
non-zero values which of the K events has occurred.
From the multivariate survival function S(t1, t2, . . . , tK |Z), we can obtain the
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marginal survival function for event type k as
Sk(t|Z) = S(t1 = 0, t2 = 0, . . . , tk = t, . . . , tK = 0|Z).
The cause-specific hazard is defined as
hk(t|Z) =





It can also be written as
hk(t|Z) = lim
δt→0




















One disadvantage of this approach is the non-identifiability of the joint distribu-
tion. In the special case of two competing risks, the two marginal distributions
can result in more than one joint distribution. When only the first event is
observed, the possible dependence between the competing events cannot be
modelled. In such situations, only the marginal distribution function and the
cause-specific hazard defined in Equation (2.1) can be modelled.
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2.1.2 Subdistribution Hazard
The other approach based on the subdistribution hazard is a result of observing
competing risks as a bivariate random variable. Such data can be presented as
a pair (T, ), where T is observed time and  is as defined earlier. If  = 0, then
T is the censored time. If  = k (k = 1, 2, . . . , K), then T is the observed time
that event of type k occurred. We then have the cumulative incidence function
(CIF), or subdistribution, for the event of type k (k = 1, 2, . . . , K) as
Fk(t|Z) = P (T ≤ t,  = k|Z).
As can be seen, the CIF is the joint probability that an event of type k occurs
at or before time t.








and this is the function that is usually modelled. The cumulative incidence





subdistribution hazard λk can be considered as the hazard function for the
improper random variable T ∗ = I( = k)× T + {1− I( = k)} ×∞.
2.1.3 Existing Methodology for Modelling Competing
Risks
To model competing risks data, the standard approach is to model the cause-
specific hazards for different failure types. An important question in statistical
analyses is whether one group of patients fare better than another group. For
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example, in considering a clinical trial on prostate cancer where treatment is
the main exposure of interest (Green and Byar 1980), it may sometimes also
be important to consider the effects of other covariates such as age and disease
history and account for these in the regression model when assessing the effect
of treatment. Thus, covariate models for competing risks have been applied to
cause-specific hazards to account for covariates like treatment. In particular,
the proportional hazards model has been widely used in competing risks situa-
tions, just as in the usual survival model (Prentice et. al, 1978; Larson, 1984).
The additive risk model was also considered as under the competing risks sce-
nario, it seemed biologically more plausible and tends to give a more intuitive
interpretation for relative survival than the multiplicative risk model (Shen and
Cheng, 1999). This is because multiplicative models postulate that the hazards
due to the event of interest are related to the hazards of the competing events.
As such, estimation under the multiplicative model can result in illogical factors
for mortality rates (Buckley, 1984).
Cause-specific hazards modelling reduces to univariate modelling since we only
consider failure times of our cause of interest, ie. Ti where i = k, and all
other failure times Ti with i 6= k (failure times not of our cause of interest) are
considered censored observations. Hence, there is only a single outcome being
recorded, with a single censoring indicator. When the cause-specific hazard
is modelled, the cumulative incidence function is often used to summarize the





where S(t|Z) is the all-cause survival function defined in Equation (2.2) and
Λk(t|Z) is the cumulative cause-specific hazard function for the k-th event. This
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is an indirect way of modelling the subdistribution. It has been noted in other
works that the effect of a covariate on the cause-specific hazards of a specific
failure type can be very different from the effect of the same covariate on the
corresponding cumulative incidence function (Gray 1988, Pepe 1991). Thus,
the focus of this chapter will be on the direct modelling of the subdistribution
through the associated subdistribution hazard.
In previous work in the literature, the cumulative incidence function has been
modelled nonparametrically, as well as with discrete covariates. Gray (1988)
considered K-sample tests to compare the cumulative incidence of a particular
failure type among different groups. Fine and Gray (1999) introduced a pro-
portional hazards model for the subdistribution. The proportional hazards was
applied to the hazard of the subdistribution given in Equation (2.3). Under Fine
and Gray’s (1999) formulation, the risk set for censoring complete data (where
the potential censoring time is always observed) at time t for failure type k was
defined as
R(t) = {i : (Ci ∧ Ti ≥ t) ∪ (i 6= k ∩ Ti ≤ t ∩ Ci ≥ t)}
and the subdistribution hazard for failure type k was specified as
λk(t|Z) = λk0(t) exp(βT0 Z(t))
where λk0 is the unspecified baseline hazard for failure type k, β0 is the unknown
p-vector regression coefficients for the possibly time-varying covariates Z , so
that the cumulative incidence function is now
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Three different scenarios were considered — complete data (without censor-
ing), censoring complete data (failure times and potential censoring times all
known) and incomplete data (when usual right censoring is present). The last
scenario involved the use of inverse probability of censoring weighting (IPCW)
techniques.
Sun et al. (2006) proposed a more general additive-multiplicative model for the
subdistribution hazard of the form
λk(t|X,Z) = α(t)TX + λk0(t) exp(βT0 Z),
where α(t) is an unknown q-vector of time-varying coefficients representing the
additive effects of covariates X on λk, β0 is a p-vector of unknown regression
coefficients denoting the multiplicative effects of covariates Z on λk and λk0 is
as defined earlier. This model was first introduced by Martinussen and Scheike
(2002) in the non-competing risk situation. Inference on the model was accom-
plished through the use of IPCW techniques to obtain score functions.
2.2 Proposed Additive Hazards Models
Let T and C be the failure and censoring times,  ∈ {1, . . . , K} be the cause
of failure (where the K causes are assumed to be observable) and Z be a p× 1
bounded vector of covariates. For the usual right-censored data, we observeX =
min(T,C), δ = I(T ≤ C) and Z. Assume that {Xi, δi, δii, Zi} are independent
and identically distributed for i = 1, . . . , n. For simplicity, we assume that C
is independent of T , given Z. Here, we take failure type 1 to be our event of
interest. Let Ni(t) be the counting process for the i-th individual, given by
Ni(t) = I(Ti ≤ t, i = 1, δi = 1).
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Here, we introduce the additive risk model for the cause-specific hazard with
fixed covariates. The model is given as
h1(t|Z) = h01(t) + βT1 Z, (2.5)
where h1 is the cause-specific hazard for event 1, h01(t) is the unknown baseline
hazard, β1 and Z are p-vector regression coefficients and covariates respectively.
In contrast to Fine and Gray’s (1999) proportional hazards model for the sub-
distribution, we propose an additive hazards model for the subdistribution. The
subdistribution hazard then takes the form
λ1(t|Z) = λ01(t) + α(t)TZ, (2.6)
where α(t) are time-varying coefficients to be estimated. This is analogous to
Aalen’s additive model. In Sun et. al (2006), α(t) is allowed to vary nonpara-
metrically. In contrast, we fix the time-varying coefficient and as an example,
assume it to be α(t) = β1e−t.
2.3 Model Fitting
Both the cause-specific hazards model and subdistribution hazards model can
be fitted using the method provided by Lin and Ying (1994). The cause-specific
hazards model is straightforward and is a direct application of the method, with
the at-risk indicator as Yi(t) = I(Ci ∧ Ti ≥ t) for the i-th individual. Under the
method by Lin and Ying (1994), the estimating equation to estimate β1 can be













































where a⊗2 = aaT , and a is a column vector.
In our additive subdistribution hazards model, we set the coefficients of the
covariates to be time-varying, where α(t) = β1e−t, and the covariates are fixed,
as shown in Equation (2.6). In order to use Lin and Ying’s method, we set β1
as the coefficient vector and Ze−t as the time-varying covariate vector Z(t).
Under the subdistribution hazards model with censoring complete data (that
is, censoring is only from administrative loss-to-follow up and the potential
censoring time is always observed; Fine and Gray, 1999), the risk indicator at
time t for the i-th individual is defined as
Yi(t) = I({Ci ∧ Ti ≥ t} ∪ {i 6= 1 ∩ Ti ≤ t ∩ Ci ≥ t}).
The estimator given in (2.8) can then be applied, where
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2.4 Theoretical Properties
In this section, we assume, without loss of generality, that T is bounded on
[0, 1]. Also, let β10 be the true value of β1 and β10 ∈ B, where B is a compact




2. (Asymptotic stability). There exists a matrix function z1 and vector func-






















4. (Asymptotic regularity conditions). Z has bounded support on Rp where
p is the dimension of Z. Also, z1 and z2 obtained in Condition 2 are









Theorem 2.4.1. (Consistency of βˆ1) Suppose that Conditions 1–4 listed above
hold, then βˆ1 P−→ β10.
Proof. To prove the consistency of βˆ1, we first write down the log-likelihood
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log(λ0(u) + βT1 Zi(u))dNi(u)−
∫ t
0
Yi(u)(λ0(u) + βT1 Zi(u))du
]
.
We now consider the process
X(β1, t) = n−1(C(β1, t)− C(β10, t))
= n−1∑ni=1 [ ∫ t0 log( λ0(u)+βT1 Zi(u)λ0(u)+βT10Zi(u)
)
dNi(u)− ∫ t0 Yi(u)(β1− β10)TZi(u)du]
and







λ0(u) + βT1 Zi(u)
λ0(u) + βT10Zi(u)
)




For each β1, X(β1, t)− A(β1, t) is a local square integrable martingale with
〈X(β1, t)− A(β1, t), X(β1, t)− A(β1, t)〉 = B(β1, t),
where 〈W,W 〉 is the predictable covariation process ofW (Andersen et al., 1993)
and












By Conditions 1, 2 and 4, we can see that B(β1) = B(β1, 1) tends to 0 in
probability. Therefore, by the inequality of Lenglart (I.2) in the appendix of
Andersen and Gill (1982), we see that X(β1) = X(β1, 1) converges to the same
limit as A(β1) = A(β1, 1) for each β1 ∈ B, where B was defined at the start of
this section. By the boundedness conditions in Condition 4, we can obtain first
and second derivatives which also have limits according to the limiting function
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We can see that at β1 = β10, the first derivative is zero and the second derivative
is the negative of a positive definite matrix. Thus for each β1 ∈ B, X(β1)
converges in probability to a concave function of β1 with a unique maximum at
β1 = β10. Since βˆ1 maximises the random concave function X(β1), it follows by
convex analysis (Andersen and Gill, 1982) that βˆ1 P−→ β10.
Theorem 2.4.2. (Asymptotic normality of βˆ1) The function n1/2(βˆ1 − β10) is
asymptotically normal with mean 0 and covariance matrix consistently estimated







and Σˆn is the estimator of the variance-covariance matrix of n−1/2U(β10), where
U(β10) is the estimating function given in Equation (2.7) evaluated at the true
value.
Proof. One of the benefits of an additive risk model for competing risks is that
the model provided by Lin and Ying (1994) has a closed form, given in Equation
(2.8). The estimating function U(β1) to obtain this estimator is defined in
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dNi(t)− Yi(t)[dΛ0(t) + βT10Zi(t)dt]














where Mi(·) is a local square integrable martingale and is defined by Ni(t) =
Mi(t) +
∫ t
0 Yi(u){dΛ0(u) + βT10Zi(u)du} for every i and t.
To prove the asymptotic normality of βˆ1, we first note that it reduces to proving
the normality of n−1/2∑ni=1 ∫ 10 {Zi(t)− Z¯(t)}dNi(t). Since
dNi(t) = dMi(t) + Yi(t)(λ0(t) + βT10Zi(t))dt,







Hence, it remains to prove n−1/2U(β10) converges weakly to a p-variate normal
with mean 0.
Firstly, we can see that U(β10) is a local square integrable martingale. Apply-
ing Rebolledo’s Central Limit Theorem for local square integrable martingales
(Andersen and Gill, 1982), we have
Hil(t) = n−1/2{Zi(t)− Z¯(t)}l






































ds. By finite interval, stability and regu-
larity conditions, the above tends to Σ defined in Condition 4.













Zi(t)− Z¯(t)}2l Yi(t){λ0(t) + βT10Zi(t)}














4n−1|Z¯(t)|2l I{n−1/2|Z¯(t)||l > ξ}Yi(t){λ0(t) + βT10Zi(t)}dt.





























|Z¯(t)|2l I{n−1/2|Z¯(t)||l > ξ}Yi(t){λ0(t) + βT10Zi(t)}dt P−→ 0. (2.12)
Using Condition 3, we have (2.10) using
P
[
∃i, t : n−1/2|Zi(t)| > ξ, βT10Zi(t) > −δ|Zi(t)|, Yi(t) = 1
]
−→ 0.






|Zi(t)|2{λ0(t)− δ|Zi(t)|}I{|Zi(t)| > n1/2ξ}dt.
When βT10Zi(t) ≤ −δ|Zi(t)|, we have λ0(t)−δ|Zi(t)| ≥ 0. Hence by Condition 4,
the quantity on the left hand side is bounded by some positive finite quantity.
Equation (2.12) is easily verified by the boundedness and regularity conditions
in 1 and 4.
Thus, n−1/2U(β10) converges weakly to a certain continuous Gaussian function.
With the process evaluated at t = 1, the covariance matrix is Σ. A consistent







where the proof is as follows.
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where dΛi(t) = dΛ0(t)+βT10
∫ t
0 Zi(u)du. It can be seen thatW (t) is a local square
integrable martingale with mean 0. We now consider W = W (∞), where we
have









Using Lenglart’s inequality (I.2) in the appendix of Andersen and Gill (1982),
we have for all δ, η > 0,
P{ sup
t∈[0,1)
|W (t)| > η} ≤ δ
η2
+ P{〈W,W 〉 > δ}.
Since 〈W,W 〉 is bounded and finite in probability, we can show that the right
hand side of the above inequality disappears and hence,
Σˆn P−→ Σ.
With this consistent estimator of the covariance matrix and the asymptotic
normality of n−1/2U(β10), we thus obtain the asymptotic normality of n−1/2(βˆ1−
β10) with covariance matrix consistently estimated by V −1n ΣˆnV −1n , where Vn is
defined in Equation (2.9) and Σˆn is the estimator of the variance-covariance
matrix of n−1/2U(β10) defined in Equation (2.13).
2.5 Simulation Studies Based on Additive Hazards Model 34
2.5 Simulation Studies Based on Additive Haz-
ards Model
The methods of data generation for the cause-specific hazards and subdistribu-
tion hazards are introduced in Section 2.5.1. Simulation results for the additive
models on both types of hazard functions are presented in Section 2.5.1.
2.5.1 Data Generation for Competing Risks
Data generation using cause-specific hazards
Simulation studies for competing risks data often utilise the latent failure time
model, which has been criticized. Since the cause-specific hazards can determine
the competing risk process, Beyersmann et al. (2009) introduce a simulation
design that depends only on the cause-specific hazards and not on unobservable
quantities. Using the simple case of a main event of interest (Event 1) and a
single competing risk (Event 2), we briefly introduce the algorithm here:
1. Specify the cause-specific hazards, h1(t) and h2(t). Here, we specify them
to be the additive hazards indicated in Equation (2.5).
2. Generate survival times T using the all-cause hazard, h1(t) + h2(t).
3. For each time T , assign event indicator  the value 1 with probability
h1(t)/(h1(t) + h2(t)). Since there are only 2 events in the simple case, it
reduces to a binomial experiment.
4. Generate external censoring times C from the Uniform[0, a] distribution
for some a > 0.
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Data generation using subdistribution hazards
Following Fine and Gray (1999), we propose a similar algorithm to generate data
from an additive subdistribution hazard (SH) of a competing risk. Denote the
SH as λ1(t|Z) = P [T ∈ dt,  = 1|(T ≥ t) ∪ ( 6= 1 ∩ T ≤ t)]. For the cumulative
incidence function (CIF) of interest, we use the additive hazards model on the
SH as denoted in Equation (2.6). The CIF can then be written as
































1− F1(t|0) = 1− P (T ≤ t,  = 1|0)
= P ( = 1|0) + P ( = 2|0)− P (T ≤ t,  = 1|0)
= P ( = 2|0) + P (T ≥ t,  = 1|0)
= P ( = 2|0) + P (T ≥ t| = 1, 0) · P ( = 1|0)
Here, we use 3 conditions:
1. P ( = 1|0) + P ( = 2|0) = 1,
2. P ( = 1|0) = p (independent of Z), and
3. T | = 1,Z = 0 follows the exponential(1) distribution.
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We then obtain
1− F1(t|0) = (1− p) + p · exp(−t)















If we specify α(t) = β1 (ie. a constant coefficient vector), we can see that when
t→∞ and Z = 0, F1(t|0)→ P ( = 1|0) = p.
However, when Z 6= 0, we get F1(t|Z)→ P ( = 1|Z) = 1 since exp(−βT1 Zt)→
0.
Thus, in this model, α(t) is constrained to be time-varying and here, we specify
the form as α(t) = β1e−t. With this form of α(t), we have








Under this specification, the covariate effect is a monotone one that decreases
towards zero over time. The time-varying effect can also be generalised to
account for different functional types.
Let T and C be the failure and censoring times and  be the cause of failure.
We assume two causes of failure — the event of interest (denoted as event 1)
and the competing risk (event 2). Let Z be a p× 1 bounded time-independent
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covariate vector. The algorithm for generating data from this model is based
on Fine and Gray (1999) and is as follows:
1. Generate Z, the covariate variable.
2. Generate the cause of failure, .
(a) Calculate F1(∞|Z) = P ( = 1|Z) =: p∗.
(b) Generate U1 from Uniform[0,1].
(c) If U1 < p∗, then set  = 1 and generate failure times from event 1.
Else, set  = 2.
3. Generate T , conditional on .
(a) If  = 1, generate T from G1(t) = P (T ≤ t| = 1,Z) using numerical
methods, where
G1(t) =
P (T ≤ t,  = 1|Z)
P ( = 1|Z)
= 1− [1− p {1− e
−t}] exp(−βT1 Z(1− e−t))
1− [1− p] exp(−βT1 Z)
i. Generate U2 from Uniform[0,1].
ii. Solve for t such that G1(t) = U2, i.e., t = G−1(U2), using R
function optim.
(b) If  = 2, generate T from P (T ≤ t| = 2,Z), which follows the
exponential distribution with rate (1 + βT2 Z)
4. Generate external censoring times C from the Uniform[0, a] distribution
for some a > 0.
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2.5.2 Simulation Results for Competing Risks
Cause-specific hazards simulations
In this section, we first present the simulation results for the cause-specific haz-
ards. We applied the method of Lin and Ying (1994) to data generated using the
method described in Section 2.5.1. For the purposes of simulation, we generated
a main event of interest (Event 1) and a competing event (Event 2). Failures
from cause 2 were taken as censored observations. A single discrete covariate Z
was generated, first from the Bernoulli(0.5) distribution, and the true parame-
ter values for the regression coefficients of the respective cause-specific additive
hazards models were assumed to be β1 = β2 = 1. Continuous covariates were
also considered in a separate simulation with a single Normal(0, 0.252) covariate
generated and parameter values set at β1 = β2 = 1.
Simulations of sample size 200 were conducted 1000 times for three degrees of
censoring (10%, 30%, 60%). Table 2.1 gives the following estimators under all
the different simulation scenarios: (i) AV E(βˆ1), estimated with the average of
βˆ1 from 1000 samples and standard errors of the average estimator given in
parentheses; (ii) SD(βˆ1), estimated with the empirical standard deviation of βˆ1
from the 1000 samples; (iii) AV E(SˆD), the average of the 1000 standard error
estimators. It can be seen from Table 2.1 that the method works well for both
continuous and discrete cases, with little bias. In the discrete case, the biases
range between 0.002 and 0.028 with standard errors of the mean estimates (in
parentheses) varying about 0.012, while the biases for the continuous case are
higher and range between 0.005 and 0.037 with standard errors of the mean
estimates varying about 0.015. The biases and standard errors tend to increase
with the level of censoring. In addition, the SD(βˆ1) values are close to those of
AV E(SˆD), although the differences are slightly larger in the continuous case.
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Estimated standard errors of β1 increased with the level of censoring in both
the discrete and continuous case.
Table 2.1: Estimating Equation Estimators for main event of interest (Event 1)
based on a Cause-Specific Hazards Model with single Z, assuming β1 = β2 = 1,
varying censoring from 10% to 60%.
Z from Bernoulli(0.5)
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 3.5] 10 1.010(0.010) 0.342 0.326
[0, 1] 30 1.002(0.012) 0.362 0.366
[0, 0.38] 60 1.028(0.015) 0.490 0.481
Z from Normal(0, 0.252)
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 5.2] 10 1.021(0.013) 0.430 0.420
[0, 1.64] 30 0.995(0.015) 0.490 0.476
[0, 0.57] 60 1.037(0.021) 0.679 0.639
We also check to see that the method works well when fitting the additive
risk model for the competing risk. In our simulations for the cause-specific
model, the competing risk was also generated from the additive risk model, as
mentioned in Section 2.5.1. Table 2.2 shows the results for a single scenario
with a single Bernoulli(0.5) covariate, where (β1, β2) = (−0.5, 1) at 10%, 30%
and 60% censoring. From Table 2.2, the biases are relatively small, with higher
biases at higher levels of censoring. The observations for SD(βˆ1) and AV E(SˆD)
were similar to the ones made for Event 1, with differences being small and the
estimations increasing with the level of censoring.
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Table 2.2: Estimating Equation Estimators of β2 for competing event (Event
2) based on a Cause-Specific Hazards Model with single Z from Bernoulli(0.5),
assuming β1 = −0.5, β2 = 1, varying censoring from 10% to 60%.
β1 = −0.5, β2 = 1
[0,a] Censoring proportion AVE(βˆ2) SD(βˆ2) AVE(SˆD)
[0, 4.7] 10 1.012(0.009) 0.285 0.282
[0, 1.49] 30 0.879(0.009) 0.251 0.280
[0, 0.51] 60 0.965(0.013) 0.385 0.397
Since we are interested to evaluate the treatment effect in most clinical trials, we
next look at the discrete Bernoulli(0.5) covariate, with differing values of β1 and
β2. We fix the value of β2 to be 1 and β1 takes on values 0.5 (adverse treatment
effect), 0 (no treatment effect) and −0.5 (beneficial treatment effect). Table
2.3 shows the results of these simulations at the same censoring proportions as
before. All estimates have very little bias (absolute bias less than 0.01) and
standard deviation estimates were similar for SD(βˆ1) and AV E(SˆD). Higher
censoring proportions result in higher standard errors and standard deviation
estimates, as well as lower biases per unit of standard error. Censoring of
10% and 60% gave biases per unit of standard error around 0.033 and 0.015
respectively.
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Table 2.3: Estimating Equation Estimators for main event of interest (Event
1) based on a Cause-Specific Hazards Model with single Z from Bernoulli(0.5),
assuming 10% to 60% censoring and varying β1 and β2.
β1 = 0.5, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 3.75] 10 0.491(0.009) 0.286 0.279
[0, 1.19] 30 0.503(0.010) 0.314 0.315
[0, 0.41] 60 0.495(0.013) 0.415 0.418
β1 = 0, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 4.15] 10 0.008(0.007) 0.239 0.234
[0, 1.3] 30 0.009(0.009) 0.272 0.268
[0, 0.46] 60 0.006(0.011) 0.352 0.352
β1 = −0.5, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 4.7] 10 −0.489(0.006) 0.195 0.195
[0, 1.49] 30 −0.499(0.007) 0.216 0.221
[0, 0.51] 60 −0.505(0.009) 0.296 0.291
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Subdistribution hazards simulations
Following the data generation method outlined in Section 2.5.1, we conduct sim-
ulations for the additive subdistribution hazards model with censoring-complete
data and report the results below. We first assume a single covariate, Z,
from the Bernoulli(0.5) distribution and that the true parameter values are
(p, β1, β2) = (0.3, 1, 1). We used three different degrees of censoring (ie. 10%,
30% and 60%), with 1000 samples, each of size 200, generated for each case. We
also consider the case of a single continuous covariate from Normal(0.5, 0.252)
distribution, with parameter values set to be the same as with the discrete case.
Table 2.4 shows the results for these simulations. The estimators here are simi-
lar to those reported previously. The biases for the discrete case (range of 0.001
– 0.025) are smaller than those for the continuous case (range of 0.01 – 0.031).
It is interesting to note that for the continuous case, lower censoring proportions
resulted in higher biases, although the biases are still small. Standard deviation
estimates were similar for both methods, regardless of censoring proportions,
and increased with the level of censoring.
We also examined simulations with varying values of p, as well as looked at
covariate effect by differing the values of β1. Tables 2.5, 2.6 and 2.7 show the
results for adverse, no and beneficial treatment effect for 3 different values of p
— 0.3, 0.6 and 0.9. Each covariate effect and level of p is examined at the same
levels of censoring as before. In all the simulations, the estimating equations
performed well, with little bias, with most of the biases ranging between 0.004
and 0.01. The largest bias observed was 0.023. The standard errors for the
average values obtained were about 0.009 and varied little regardless of degree of
censoring or the values of p or (β1, β2). The empirical and model variances were
similar. There were larger variance estimators at higher degrees of censoring.
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Table 2.4: Censoring Complete Estimating Equation Estimators for main event
of interest (Event 1) based on a Subdistribution Hazards Model with single Z,
assuming β1 = β2 = 1, varying censoring from 10% to 60%.
Z from Bernoulli(0.5)
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 8] 10 0.999(0.010) 0.323 0.319
[0, 2.5] 30 1.004(0.011) 0.348 0.336
[0, 0.85] 60 1.025(0.012) 0.365 0.386
Z from Normal(0.5, 0.252)
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 7] 10 1.031(0.020) 0.649 0.637
[0, 2.4] 30 1.024(0.021) 0.669 0.661
[0, 0.82] 60 1.010(0.025) 0.760 0.771
However, given the degree of censoring and combination of (β1, β2), the variance
estimators were similar for varying p. This seems to indicate a robustness in our
estimation method in relation to p, since p is not a parameter that is estimated
in our proposed model.
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Table 2.5: Censoring Complete Estimating Equation Estimators for main event
of interest (Event 1) based on a Subdistribution Hazards Model with single Z
from Bernoulli(0.5) and p = 0.3, assuming 10% to 60% censoring and varying
β1 and β2.
β1 = 0.5, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 8] 10 0.506(0.009) 0.288 0.285
[0, 2.65] 30 0.496(0.009) 0.304 0.297
[0, 0.9] 60 0.507(0.011) 0.354 0.343
β1 = 0, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 8.2] 10 0.007(0.008) 0.248 0.251
[0, 2.58] 30 −0.004(0.008) 0.266 0.264
[0, 0.87] 60 −0.010(0.010) 0.305 0.306
β1 = −0.5, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 7.5] 10 −0.508(0.007) 0.224 0.221
[0, 2.33] 30 −0.495(0.007) 0.233 0.233
[0, 0.78] 60 −0.511(0.009) 0.269 0.275
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Table 2.6: Censoring Complete Estimating Equation Estimators for main event
of interest (Event 1) based on a Subdistribution Hazards Model with single Z
from Bernoulli(0.5) and p = 0.6, assuming 10% to 60% censoring and varying
β1 and β2.
β1 = 0.5, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 8.76] 10 0.505(0.009) 0.277 0.283
[0, 2.72] 30 0.502(0.009) 0.296 0.297
[0, 0.92] 60 0.506(0.011) 0.350 0.342
β1 = 0, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 9] 10 −0.002(0.008) 0.250 0.249
[0, 2.83] 30 0.008(0.008) 0.267 0.263
[0, 0.97] 60 0.011(0.010) 0.302 0.301
β1 = −0.5, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 9] 10 −0.500(0.007) 0.220 0.221
[0, 2.86] 30 −0.501(0.007) 0.226 0.230
[0, 0.98] 60 −0.495(0.008) 0.270 0.262
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Table 2.7: Censoring Complete Estimating Equation Estimators for main event
of interest (Event 1) based on a Subdistribution Hazards Model with single Z
from Bernoulli(0.5) and p = 0.9, assuming 10% to 60% censoring and varying
β1 and β2.
β1 = 0.5, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 8.8] 10 0.514(0.009) 0.281 0.284
[0, 2.79] 30 0.477(0.009) 0.303 0.297
[0, 0.94] 60 0.496(0.011) 0.332 0.340
β1 = 0, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 9.7] 10 −0.018(0.008) 0.249 0.252
[0, 3.1] 30 −0.007(0.008) 0.264 0.261
[0, 1.09] 60 0.014(0.009) 0.296 0.294
β1 = −0.5, β2 = 1
[0,a] Censoring proportion AVE(βˆ1) SD(βˆ1) AVE(SˆD)
[0, 10.8] 10 −0.501(0.007) 0.223 0.220
[0, 3.5] 30 −0.504(0.007) 0.226 0.228
[0, 1.27] 60 −0.492(0.008) 0.246 0.250
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2.6 Application to Prostate Cancer Dataset
The dataset application in this chapter is a randomised clinical trial compar-
ing treatment for patients with prostate cancer in stages 3 and 4. It was first
analysed by Green and Byar (1980). This dataset consisted of 506 patients
randomly allocated to one of four different doses of diethylstilbestrol (DES)
(placebo, 0.2mg, 1mg and 5mg daily). Treatment effect was examined for the
risk of death from different causes. Green and Byar (1980) applied the propor-
tional hazards model with an exponential baseline on the survival times and
considered interaction effects between treatment and other covariates, without
accounting for the competing risks nature of the data. Kay (1986) re-examined
the data using a subset of 483 patients, those with complete information on
all the relevant variables, and applied the proportional hazards model on the
cause-specific hazards. This allowed a direct measure of the effect of treatment
on the different causes of death — cancer, cardiovascular disease (CVD) and
other causes. Cheng et al. (1998) also analysed this dataset using the same
subset of patients but with different classifications of death, that is, death from
prostate cancer, CVD and other causes. They predicted the cumulative inci-
dence function (defined in Section 2.1.2) based on proportional hazards on the
cause-specific hazards. Ng and McLachlan (2003) used the same subset of data
with the same endpoints as Cheng et al. (1998) and proposed a semi-parametric
mixture model to account for the competing risks nature of the data.
We aim to examine this dataset on prostate cancer using the same failure types
as Kay (1986) — death due to cancer, death due to CVD and death due to
other causes. There were 483 patients in the subset with complete information.
For analysis purposes, the four different doses of DES were classified into two
groups — low-dose DES (0 and 0.2mg) and high-dose (1.0mg and 5.0mg). The
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Table 2.8: Coding of the covariates in the prostate cancer data (Green and
Byar, 1980)
Value
Variable 0 1 2
RX 0 (placebo) and 0.2mg 1.0mg and 5.0mg
AG <75 years 75 to 79 years ≥ 80 years
WT ≥ 100 80 to 99 <80
PF Normal Limited
HX No Yes
HG ≥ 12 g/100 ml 9–11.9 g/100 ml <9 g/100 ml
SZ < 30cm2 ≥ 30cm2
SG ≤ 10 >10
treatment indicator, RX, assigned value 0 for the low-dose group and value
1 for the high-dose group. Following the previous work of Kay (1986), there
were seven other covariates included in the model: age (AG), weight index
(WT), performance rating (PF), history of cardiovascular disease (HX), serum
hemoglobin (HG), size of primary lesion (SZ) and Gleason stage/grade category
(SG). The coding of these covariates are according to Green and Byar (1980)
and is given in Table 2.8.
Of the 483 patients, there were 241 patients in the low-dose group and 242 pa-
tients in the high-dose group. There were 344 deaths in total, with 149 cancer
deaths, 139 CVD deaths and 56 deaths from other causes. Other causes in-
clude deaths from respiratory diseases, other specified or unspecified noncancer
causes and unknown causes. The remaining 139 patients were censored, giving
a censoring proportion of 28.8%. While Kay (1986) and Cheng et al. (1998) use
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goodness-of-fit tests to suggest that the Cox model on the cause-specific hazards
is a reasonable fit to the data, we apply the additive risk model on the three
cause-specific hazards to examine excess risk. The estimates of the regression
coefficients based on the additive risk model outlined earlier for the three causes
are given in Table 2.9. We fit the treatment indicator as well as the seven other
covariates, keeping in line with previous analysis work. We also fit the additive
risk model for the overall survival. The survival time was measured in months.
Table 2.9: Parameter estimates for overall survival and cause-specific hazards
(data from Green and Byar, 1980).
. Cause-specific
Coefficient Overall Survival Cancer CVD Others
RX −0.0029 −0.0043 * 0.0030 * −0.0017
(0.0022) (0.0015) (0.0014) (0.0009)
AG 0.0066 * 0.0000 0.0035 * 0.0031 *
(0.0023) (0.0014) (0.0015) (0.0012)
WT 0.0036 0.0014 0.0004 0.0018 *
(0.0020) (0.0014) (0.0012) (0.0008)
PF 0.0131 * 0.0047 0.0058 0.0025
(0.0062) (0.0041) (0.0039) (0.0025)
HX 0.0090 * −0.0004 0.0094 * −0.0000
(0.0025) (0.0015) (0.0017) (0.0010)
HG 0.0079 * 0.0063 * 0.0002 0.0014
(0.0035) (0.0025) (0.0019) (0.0014)
SZ 0.0203 * 0.0183 * −0.0009 0.0029
(0.0058) (0.0048) (0.0025) (0.0021)
SG 0.0077 * 0.0101 * −0.0008 −0.0015
(0.0023) (0.0016) (0.0015) (0.0009)
Standard errors given in parentheses and * indicates significance at 5% level.
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As shown from Table 2.9, the conclusion with regards to the statistical signif-
icance of individual covariates are similar to that of Kay (1986). For overall
survival, the treatment effect is not significant, with the high-dose group hav-
ing higher survival probability. The remaining covariates have significant effect,
with WT having marginal significance and worse survival for increased WT. As
for the cause-specific analysis, it can be seen that the high-dose DES group does
better with reduced risk of cancer death (estimated excess risk = −0.00426 per
month), but fared worse with increased risk of CVD death (estimated excess risk
= 0.00303 per month). Hemoglobin, tumour size and stage/grade significantly
affected the risk of cancer death, with higher values associated with higher risk.
Older patients had a higher risk of CVD death, as are those with a history of
CVD. Older patients with a higher value for the weight index were at higher risk
of deaths from other causes (noncancer, nonCVD or unknown), with a marginal
beneficial treatment effect.
We now examine the same dataset using the subdistribution hazards model
described in Section 2.2, Equation (2.6), with estimators defined in Section 2.3.
In the model, we assumed that the regression coefficients are time-varying and
take the form α(t) =β1e−t, where α and β1 are column vectors of length 8,
corresponding to the eight covariates fitted. Table 2.10 shows the estimators of
β1 when fitted for the subdistribution hazards for each of the three competing
events — cancer death, CVD death and death due to other causes. Figure
2.1 shows the cumulative incidence functions comparing treatment for each of
the three causes of death, when adjusted for the average value of the other
covariates.
The results indicate a lack of a significant treatment effect for the subdistribu-
tion hazards model with time-varying coefficients of the form β1e−t. However,
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Figure 2.1: Cumulative incidence functions (CIF) comparing low- and high-
dose DES patients with average values of other covariates (data from Green
and Byar, 1980). CIFs are plotted for: (i) cancer, (ii) cardiovascular, (iii) other
causes of death.
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Table 2.10: Parameter estimates for subdistribution hazards (data from Green
and Byar, 1980).
Subdistribution hazard
Coefficient Cancer CVD Others
RX 0.0122 0.0386 −0.0079
(0.0179) (0.0255) (0.0189)
AG 0.0184 0.0102 0.0107
(0.0133) (0.0244) (0.0249)
WT −0.0130 −0.0004 0.0123
(0.0149) (0.0159) (0.0070)
PF 0.0208 0.0054 0.0797
(0.0415) (0.0517) (0.0637)
HX −0.0144 0.0778 * −0.0065
(0.0191) (0.0282) (0.0209)
HG 0.0235 0.0281 0.0613
(0.0238) (0.0349) (0.0453)
SZ 0.0641 0.0014 −0.0006
(0.0525) (0.0416) (0.0396)
SG 0.0229 0.0147 0.0145
(0.0180) (0.0247) (0.0170)
Standard errors given in parentheses and * indicates significance at 5% level.
we can see that under the subdistribution hazards model, the covariate effects
differ from those under the cause-specific hazards model, in particular, the treat-
ment effect on cancer deaths. Since the risk varies over time, we will take time
at month 1 as an example. Under the cause-specific hazards model, patients
receiving high-dose DES had a lower risk of cancer death. However, under the
subdistribution hazards model, patients receiving high-dose DES had a higher
instantaneous risk of cancer death such that at month 1, high-dose patients had
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a 0.0122e−1 = 0.00449 higher risk than low-dose patients.
Using the model from Table 2.10, we can estimate the probability of different
death outcomes over time for patients with different characteristics. A patient
between 75–79 years of age with a moderate weight index and has a history of
CVD has an estimated probability of 0.25 of cancer death within 4 years if he
receives high-dose DES. A patient with the same characteristics would die from
cardiovascular disease within 4 years with probability 0.3, and from other causes
with probability 0.08. Thus, for patients who have a history of CVD, cancer
death may not be the primary concern. On the other hand, a patient between
75–79 years of age with a moderate weight index and a primary lesion more
than 30cm2 has a probability of 0.30 of cancer death within 4 years, whereas
the estimated probability of cardiovascular death and other causes is 0.25 and
0.06 respectively.
2.7 Discussion
In this chapter, we applied the additive hazards model to competing risks via
two approaches — the cause-specific hazard and the subdistribution hazard,
with the focus on the estimation of the regression coefficients. The purpose of
using additive hazards models is to act as a complement to the widely-used pro-
portional hazards models which examine relative risk, even in competing risks
data. Using counting process theory, we prove the consistency and asymptotic
normality of the estimators. Simulations were conducted from new approaches
for both the cause-specific and subdistribution hazards. Results from the sim-
ulations show that the data generation and estimation procedures work well.
Application of the methods to the prostate cancer dataset yields similar conclu-
sions as Kay (1986) under the cause-specific hazards model. We also analysed
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the data from the subdistribution hazards approach, to see if it yielded a dif-
ferent result from the cause-specific hazards approach used earlier and in other
literature. Fine (1999) examines this dataset using a general class of transfor-
mation models for the cumulative incidence function. The proportional hazards
and odds model was selected for cancer and CVD outcomes respectively. Our
results differ from Fine (1999) as we observed that high-dose DES increased the
incidence of death, while Fine (1999) observed otherwise. However, we observe
similar results for the modelling CVD cumulative incidence in that high-dose
DES increases the incidence of CVD death. While the additive subdistribution
hazards model does not seem a reasonable fit for the prostate cancer dataset,
one reason for this is that we have specified the form of the time-varying func-
tion of the regression coefficient. Further work could look at other time-varying
forms that could be used for the subdistribution model.
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Chapter 3
A Frailty Model with
Conditional Additive Hazards
for Semi-Competing Risks Data
3.1 Introduction
In studies involving time-to-event outcome, a subject may experience multiple
failures, such as repeated episodes of infection, or distant or local recurrences
in cancer studies. In the context of competing risks, the failures are usually
of different types. In this chapter, we consider a variation of the competing
risks problem, known as semi-competing risks (Fine, Jiang and Chappell, 2001)
where a non-terminal event is censored by a terminal event but not vice versa.
Under the semi-competing risks framework, each subject is associated with two
potential failure times — a non-terminal failure (e.g. relapse) and a terminal
failure (e.g. death). It is biologically plausible that the failure times observed
for each individual may be strongly correlated.
As an example, consider the randomized clinical trial for nasopharyngeal cancer
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(NPC), conducted in Singapore between September 1997 and May 2003 (Wee et
al., 2005). This study compared standard radiotherapy treatment to chemora-
diotherapy followed by adjuvant chemoradiotherapy on patients with American
Joint Committee on Cancer/International Union Against Cancer (1997) Stage
3 and 4 nasopharyngeal cancer of the endemic variety. The end-points of inter-
est were distant metastasis and disease-free survival. In both cases, relapse is
the non-terminal event of interest, but could be censored by death. Wee et al.
(2005) used competing risks methodology to analyse the data, but this does not
utilise the additional information provided by the dependent censoring structure
of semi-competing risks.
Existing literature uses the method of copulas to model the joint survival func-
tion between the two failure times, both without covariates (Fine, Jiang and
Chappell, 2001; Jiang et al., 2005; Wang, 2003; Lakhal et al., 2008) and with
covariates (Peng and Fine, 2007; Hsieh and Wang, 2008). These methods were
discussed in Chapter 1. In this chapter, we introduce an alternative way to fit
such data that has a straightforward way of incorporating covariates and mea-
suring the dependent relationship between T1 and T2. Instead of modelling the
joint survival function, we propose to model the hazards of each branch of the
compartment model in Figure 1.1, conditional on a frailty term. In addition,
we model the baseline hazards using B-splines (de Boor, 1978).
Splines are piecewise polynomials satisfying continuity constraints at the knots
joining the pieces. As the number of knots increases, very flexible families of
models are created, so spline methods are a good alternative to exploring the
nature of relationships, especially those of a continuous smooth form. The
shape of a spline function depends on: (i) the order of the function; (ii) the
knot sequence; and (iii) the continuity conditions at each knot. Splines can
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be expressed as a linear combination of basis functions — functions that span
the space of all piecewise polynomials with a specific order, knot sequence and
continuity conditions. Commonly used spline bases include the truncated power
basis and the B-spline basis.
Such methods have been considered for modelling in survival analysis. Splines
using the truncated power basis were considered by Etezadi-Amoli and Ciampi
(1987) in the modelling of the baseline hazard in the extended hazard regression
model, which is a generalisation that includes the proportional hazards and
accelerated failure time models. Cubic B-splines were used by Sleeper and
Harrington (1990) as regression splines (without penalty functions) and by Gray
(1992, 1994) through penalized likelihoods to model arbitrary covariate effect as
an extension to the Cox model. Rosenberg (1995) also used cubic B-splines for
hazard function estimation without covariates. Cubic splines are often sufficient
and flexible enough to reflect the changes in the hazard function.
In this thesis, we focus our use of splines to that of cubic B-splines in the fitting
of the baseline hazards in our conditional additive risk model for semi-competing
risks data. We also apply this method to the NPC dataset and aim to model the
hazards of relapse, death without relapse and death after relapse respectively,
adjusting for treatment, nodal status and TNM staging.
3.2 Proposed Model and Estimation
3.2.1 Additive Hazards for Semi-Competing Risks
Let T1 and T2 be the failure times of the non-terminal and terminal events
respectively. There is a censoring time C that is independent of both T1 and
T2, such as administrative loss to follow-up. Denote the observed failure times
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as Y = min(T2, C) and X = min(T1, Y ). We have the corresponding event
indicators as δ1 = I(T1 < Y ) and δ2 = I(T2 < C) for the occurrence of the
non-terminal and terminal events respectively. The observed data for the i-th
individual is then Ωi = {Xi, δi1, Yi, δi2,Zi}, where Zi is a p× 1 covariate vector.
Under the additive risk frailty model, conditional on the frailty, the hazards
model is an additive one. We have 3 hazard functions for each individual — one
for time to relapse, one for time to death without relapse and one for time to
death after relapse. Their relationships can be seen in the compartment model
shown in Figure 1.1 of Chapter 1. Here we restate the set of of hazard functions
for the i-th individual from Chapter 1:
λ1(t|Ti2 ≥ t, γi,Zi) = γi(λ01(t) + βT1Zi(t)),
λ2(t|Ti1 ≥ t, γi,Zi) = γi(λ02(t) + βT2Zi(t)),
λ3(t|Ti1 ≤ t, γi,Zi) = γi(λ03(t) + βT3Zi(t)), (3.1)
where γi (i = 1, . . . , n) is independent and identically distributed from the
Gamma distribution with shape θ−1 and scale θ, such that the mean of the
frailty parameter is 1 and the variance is θ. We assume the Gamma dis-
tribution here for mathematical convenience. Conditional on the frailty, the
above hazards are independent for each individual. It is of interest to esti-
mate {β1,β2,β3, θ,Λ01(t),Λ02(t),Λ03(t)}. In general, λ3(t2|t1, γ,Z) can depend
on both t1 and t2. In this thesis, we consider the semi-Markov process, where
λ3(t2|t1, γ,Z) = λ3(t2−t1|γ,Z) which depends only on the time between relapse
and death.
A simpler, restricted model that might be of interest is to assume β2 = β3 and
λ02 = λ03. In this restricted model, the dependence between T1 and T2 is fully
3.2 Proposed Model and Estimation 59
captured by the frailty parameter, γ.
3.2.2 Estimation of Additive Risk Frailty Model
For the three unknown baseline hazards, we propose to use cubic B-splines with
M breakpoints {ξ1, . . . , ξM}, making the maximization of the likelihood function
over a finite dimensional space. This is in contrast to the nonparametric plug-in
estimator provided by Lin and Ying (1994) in the usual survival setting. With




cmjBmj(t), m = 1, 2, 3, (3.2)
where {Bm1(t), . . . , BmJ(t)} are the B-spline basis functions for each of the three
hazards facing an individual.
Three important mathematical properties of cubic B-splines (deBoor, 1978) are,
for each m = 1, 2, 3,
1. Bmj(t) = 0 if t /∈ (τj, τj+4),
2. Bmj(t) > 0 if τj < t < τj+4,
3. ∑Jj=1Bmj(t) = 1,
where the knot sequence τ here is defined to be τ= {a = τ1 = . . . = τ4, τ5 =
ξ1, . . . , τ4+M = ξM , τ4+M+1 = . . . = τM+8 = b} and a and b are the observed
minimum and maximum of the survival times. In this thesis, we consider only
splines that do not require estimation of the number (M) and placement of the
knots.
We next set up the likelihood under the additive hazards frailty model. Un-
der the assumption of independent hazards given the frailty, the conditional
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likelihood for the i-th individual is
Lci = [γi{λ01(Xi) + βT1 Zi}]δi1 [γi{λ02(Yi) + βT2 Zi}]δi2(1−δi1)




Λ01(Xi) + (βT1 Zi)Xi + Λ02(Xi)
+(βT2 Zi)Xi + (Λ03(Yi)− Λ03(Xi)) + (βT3 Zi)(Yi −Xi)
}]
.
The unconditional observed likelihood for the i-th individual is obtained by
integrating out the frailty term, which we have assumed to follow the Gamma




λ01(Xi) + βT1 Zi
]δi1[
λ02(Yi) + βT2 Z
]δi2(1−δi1)[






Λ01(Xi) + (βT1 Zi)Xi + Λ02(Xi)
+(βT2 Zi)Xi + (Λ03(Yi)− Λ03(Xi)) + (βT3 Zi)(Yi −Xi)
}]1/θ+δi1+δi2
.







λ01(Xi) + βT1 Zi
]
+ δi2(1− δi1) log
[




λ03(Yi) + βT3 Zi
]
+ δi1δi2 log(1 + θ)
−(1
θ









Xi + (Λ03(Yi)− Λ03(Xi)) + (βT3 Zi)(Yi −Xi)
}], (3.3)
where λ0m(t) is estimated by Equation (3.2) and Λ0m(t) (m = 1, 2, 3) is esti-









The loglikelihood equation (3.3) is the function we aim to maximise with respect
to the parameters ϑn = (βT1 ,βT2 ,βT3 , θ, ϕn = (G01, G02, G03)T ). Score functions
and the hessian matrix are accordingly calculated for the information matrix.
3.3 Theoretical Properties
By parameterizing the baseline hazard, we consider the space Θn, spanned by
the parameters we aim to estimate, in this case, ϑn, which are the regression
coefficients β1, β2, β3, the variance of the Gamma frailty distribution, θ, and
the spline approximations to the baseline hazard functions, ϕn. This space
is known as a sieve space (Grenander, 1981) and approximates the infinite-
dimensional parameter space Θ, spanned by {β1, β2, β3, θ,Λ01(t),Λ02(t),Λ03(t)}.
Here, the estimator ϑˆn is obtained by maximizing the empirical criterion func-
tion `n(ϑ) = (1/n)
∑n
i=1 `(ϑ,Ωi), where `n(ϑ) is the loglikelihood function de-
fined in Equation (3.3) multiplied by a constant (1/n) and `(ϑ,Ωi) is the con-
tribution of the i-th individual to the loglikelihood.
In this section, we assume that T1 and T2 are bounded on [0, 1]. Define Hr
as the collection of all functions on [0, 1] whose mth order derivative satisfies
the Hölder condition of order v with r = m + v. That is, for any h ∈ Hr,
there exists a positive constant c such that |h(m)(s) − h(m)(t)| ≤ c|s − t|v, for
any 0 ≤ s, t ≤ 1. Let Cr be the space of all bivariate functions h(t1, t2) on
[0, 1]2 such that D(u1,u2)h = ∂u1+u2h/∂u1t1∂u2t2 is continuous and Lipschitz of
order v:
∥∥∥D(u1,u2)(T )−D(u1,u2)(S)∥∥∥ ≤ W0|T − S|v for any T, S ∈ [0, 1]2 and
u1 + u2 < r − v, where W0 is a finite constant. Also let Pϑ0 be the probability
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measure under the true model parameters and Pn be the empirical probability
measure.
Before we examine some of the properties of ϑˆn, the MLE of the sieve space,
we first give some conditions needed for the following theorems. Denote ϑ0 as
the true values of the parameters to be estimated.
1. T1 and T2 have supports on [0, 1] and Z has bounded support on Rp where
p is the dimension of Z.
2. β0 = (βT10,βT20,βT30)T ∈ B where B is a compact set in R3p with nonempty
interior. Also, λ01, λ02 ∈ Hr and λ03 ∈ Cr.
3. r ≥ 2 where r is the measure of smoothness of λj in the definitions of Hr
and Cr.
Theorem 3.3.1. (Consistency of estimator ϑˆn). Suppose the conditions (1–3)
above hold true, then ϑˆn is a consistent estimator of ϑ0.
Proof. The proof follows closely to Xue et al. (2004). Let Fn = {`(ϑ, ·) : ϑ ∈
Θn} and N(n,Fn, Pn) be the covering number defined by Pollard (1984). Using












|Pn`− P`| > 8n
}
< +∞,
where P = Pϑ0 and by Borel-Cantelli lemma, under Pϑ0 ,
sup
ϑ∈Θn
|Pn`− P`| −→ 0, a.s.. (3.5)





ζ2n = Pn`(ϑ0, ·)− P`(ϑ0, ·). (3.6)
Denote K = {ϑ : d(ϑ,ϑ0) ≥ ,ϑ ∈ Θn}, where we define a distance metric
d as the sum of the L2 distance between each parameter in ϑ, based on the






P`(ϑ,Ω)− Pn`(ϑ,Ω) + Pn`(ϑ,Ω)
}
≤ ζ1n + inf
K
Pn`(ϑ,Ω) (3.7)





= ζ2n + P`(ϑ0,Ω) (3.8)
The choice of the sieve space results in infK P`(ϑ,Ω)− P`(ϑ0,Ω) = δ, where
δ > 0. Hence, by (3.7) and (3.8),
inf
K
P`(ϑ,Ω) ≤ ζ1n + ζ2n + P`(ϑ0,Ω)
= ζn + P`(ϑ0,Ω),
where ζn = ζ1n + ζ2n. Thus we get ζn ≥ δ. Furthermore, we have {ϑˆn ∈ K} ⊆
{ζn ≥ δ}. By (3.5) and the Strong Law of Large Numbers, we have ζ1n = o(1),








n=k{ζn ≥ δ}, we
get d(ϑˆn,ϑ0) P−→ 0 and thus prove the consistency of ϑˆn.
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Theorem 3.3.2. (Asymptotic normality of ϑˆn). Let η = (βT1 ,βT2 ,βT3 , θ)T . If
the conditions (1–3) above hold, then
√
n(ηˆ − η0) is asymptotically normal.
Proof. This proof follows closely to Murphy (1995). To obtain the score func-
tions, one can use the usual method of differentiating the loglikelihood `n with
respect to the parameters given in ϑ. An equivalent method would be to con-
sider one-dimensional submodels through the estimators and differentiate at the
estimator. Set βjt = th1j +βj, θt = th2 + θ and Λ0jt(·) =
∫ ·
0[1 + th3j(u)]dΛˆ0j(u)
for j = 1, 2, 3, where h1j are vectors of length p, h2 is a scalar and h3j are
functions. Use these models in `n and differentiate and set t = 0 to obtain
Sn(ϑ). Note that the estimator that maximises `n will have Sn(ϑˆ) = 0. Sn can
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where h1 = (hT11, hT12, hT13), h3 = (h31, h32, h33), Λ = Λ1(Xi) + Λ2(Xi) + (Λ3(Yi)−
Λ3(Xi)) and Λj(t) = Λ0j(t) + βTj Zit for j = 1, 2, 3.
We begin by proving the conditions in Theorem 2 of Murphy (1995). We obtain
the condition that
√
n(Sn(ϑ0)− S(ϑ0)) converges weakly to a normal distribu-
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tion with mean 0, by central limit theorem and continuous mapping theorem,
where Sn is the empirical score function of the likelihood and S is the asymp-
totic version of Sn. The approximation condition is a technical proof and is
omitted here.
Denote S˙(ϑ0) as the linear operator on the set of all linear combinations of
(ϑ − ϑ0) for all ϑ ∈ Θ. The classical relationship between the asymptotic
variance of the score function (the information matrix for ϑ) and the derivative
of the score equation, −S˙(ϑ0) holds. By writing S(ϑ) as a linear combination
of βˆ − β0, θˆ − θ0 and d(Λˆ0j − Λ0j) plus error terms, we obtain −S˙(ϑ0)(ϑ0)(h)
as the variance for
√
nSn(ϑ0)(h). We thus get
S(ϑˆ)− S(ϑ0) = S˙(ϑ0)(ϑˆ− ϑ0).
Given the convergence to normality of
√
n(Sn(ϑ0) − S(ϑ0)) and the fact that







n((Sn − S)(ϑˆ)− (Sn − S)(ϑ0)),




nS˙(ϑ0)(ϑˆ− ϑ0) + oP (1).
With the asymptotic normality of
√
n(Sn(ϑ0)− S(ϑ0)) and the invertibility of
S˙(ϑ0), we get the convergence in distribution of
√
n(ϑˆ − ϑ0) to the normal
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distribution. We now write
√
ngT1 (βˆ − β0) +
√





where (gT1 , g2, g31, g32, g33) are coefficients to form linear combinations of
√
n(ϑˆ−
ϑ0). Thus, by Cramer-Wold device (van der Vaart, 1998) and setting g3j = 0
for j = 1, 2, 3, we have the asymptotic normality of
√
n(ηˆ − η0).
3.4 Simulation Studies Based on Additive Risks
Frailty Model
3.4.1 Data Generation for Semi-Competing Risks
Based on the conditional independence of the hazard functions, we first generate
covariate vector Z and the gamma frailty term. Given the covariate values and
the frailty, we then generate two independent times, T1 (time to non-terminal
event) and T2 (time to terminal event), from their respective distributions based
on λ1 and λ2 from Equation (3.1). If T1 > T2, then we consider the non-terminal
event as censored. Conversely, if T1 < T2, then the non-terminal event has
occurred and we generate a third time from the third branch of the compartment
model to obtain the time to the terminal event after the non-terminal event has
occurred. Censoring times, C, are generated independently of T and from the
Uniform[0, a] distribution for some a > 0.
3.4.2 Simulation Results for Additive Risk Frailty Model
We consider the simple case of a single discrete covariate Z generated from the
Bernoulli(0.5) distribution. Simulations were conducted for a sample size of
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400, and at two degrees of censoring, 10% and 30%. We fix the baseline hazard
to be from the exponential distribution with mean 1. Two sets of true values
are considered for the three regression coefficients of the respective hazards —
(β1, β2, β3) = (1, 1, 1) and (β1, β2, β3) = (0.5, 1, 2); and the true value of θ for
the Gamma frailty distribution is first set at 0.95.
We generate 1000 simulations for each combination of censoring, regression co-
efficients and θ. Table 3.1 shows the results and for each parameter combination
gives: (i) the Estimate (Est), the average from 1000 estimates; (ii) the Empir-
ical Standard Error (EmpSE), the standard deviation of the 1000 estimators;
(iii) the Model Standard Error (ModSE), the average of 1000 standard error
estimators, using the information matrix. These notations are similar to those
reported in the simulations in Chapter 2, where Est, EmpSE and ModSe are
similar to AV E(βˆ1), SD(βˆ1) and AV E(SˆD) in Chapter 2 respectively. We also
conducted 1000 simulations for different levels of censoring and regression co-
efficients, and varying θ. Tables 3.2 and 3.3 shows the results for θ = 0.5 and
1.5 respectively. The tables indicate that the biases are relatively small and
are about 10% of the true value. All the simulations indicate that larger values
of the parameters result in larger standard errors. Similar observations can be
made for higher percentages of censoring. In addition, standard errors increase
slightly with censoring. Varying values of θ do not affect the estimates much.
Figure 3.1 shows the plots of the spline estimators of the basline survival function
for the time to relapse. Under the simulation, the true survival function is
S0(t) = e−t and is indicated on the diagram with the solid black line. The grey
lines are the estimators obtained from each of the 1000 samples. As can be
seen, the spline estimators approximate the general shape of the true survival
function well.
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Table 3.1: Estimators for Additive Risk Frailty Model for Semi-Competing Risks
Data with single Z from Bernoulli(0.5) and θ = 0.95, with 10% and 30% cen-
soring and varying β.
(β1, β2, β3) = (1, 1, 1)
[0,a] Cens Est EmpSE ModSE
[0, 12] 10% β1 1.094 0.38 0.38
β2 1.066 0.36 0.38
β3 1.092 0.19 0.23
θ 1.045 0.17 0.19
[0, 2.4] 30% β1 1.108 0.40 0.41
β2 1.087 0.38 0.41
β3 1.090 0.46 0.51
θ 1.071 0.23 0.24
(β1, β2, β3) = (0.5, 1, 2)
[0,a] Cens Est EmpSE ModSE
[0, 12] 10% β1 0.549 0.28 0.31
β2 1.066 0.35 0.37
β3 2.162 0.64 0.67
θ 1.046 0.17 0.20
[0, 2.4] 30% β1 0.584 0.31 0.34
β2 1.105 0.39 0.41
β3 2.154 0.72 0.77
θ 1.083 0.22 0.25
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Table 3.2: Estimators for Additive Risk Frailty Model for Semi-Competing Risks
Data with single Z from Bernoulli(0.5) and θ = 0.5, with 10% and 30% censoring
and varying β.
(β1, β2, β3) = (1, 1, 1)
[0,a] Cens Est EmpSE ModSE
[0, 6.6] 10% β1 1.127 0.35 0.35
β2 1.117 0.35 0.34
β3 1.120 0.40 0.41
θ 0.608 0.16 0.16
[0, 1.7] 30% β1 1.132 0.38 0.39
β2 1.120 0.37 0.39
β3 1.105 0.45 0.49
θ 0.625 0.21 0.21
(β1, β2, β3) = (0.5, 1, 2)
[0,a] Cens Est EmpSE ModSE
[0, 6.6] 10% β1 0.562 0.27 0.28
β2 1.103 0.34 0.33
β3 2.182 0.59 0.61
θ 0.592 0.16 0.16
[0, 1.7] 30% β1 0.591 0.30 0.32
β2 1.140 0.37 0.38
β3 2.194 0.69 0.73
θ 0.640 0.22 0.22
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Table 3.3: Estimators for Additive Risk Frailty Model for Semi-Competing Risks
Data with single Z from Bernoulli(0.5) and θ = 1.5, with 10% and 30% censoring
and varying β.
(β1, β2, β3) = (1, 1, 1)
[0,a] Cens Est EmpSE ModSE
[0, 30] 10% β1 1.085 0.41 0.42
β2 1.067 0.41 0.41
β3 1.081 0.46 0.47
θ 1.616 0.23 0.23
[0, 3.9] 30% β1 1.104 0.43 0.45
β2 1.106 0.42 0.45
β3 1.103 0.50 0.54
θ 1.651 0.28 0.28
(β1, β2, β3) = (0.5, 1, 2)
[0,a] Cens Est EmpSE ModSE
[0, 30] 10% β1 0.571 0.32 0.34
β2 1.099 0.39 0.41
β3 2.192 0.69 0.72
θ 1.640 0.24 0.23
[0, 3.9] 30% β1 0.580 0.34 0.37
β2 1.124 0.43 0.45
β3 2.207 0.79 0.82
θ 1.662 0.29 0.31
3.5 Application to NP01 Clinical Trial 71
Figure 3.1: Plot of 1000 estimators of the baseline survival functions for time
to relapse. Estimators obtained using splines. Bold line indicates true survival
function.
3.5 Application to NP01 Clinical Trial
The dataset used in this chapter was briefly mentioned in Chapter 1 and is a
randomised clinical trial conducted in Singapore comparing two treatments on
nasopharyngeal cancer (Wee et al., 2005). In the trial (NP01) conducted be-
tween September 1997 and May 2003, patients may experience the non-terminal
event of interest — cancer relapse of any type, and/or the terminal event —
death. There were 221 patients who were randomly assigned in total, with
110 receiving radiotherapy (RT) alone and 111 receiving chemoradiotherapy
(CRT). Of the 110 patients receiving radiotherapy alone, there were 48 relapses
and 44 deaths (of which 39 were disease related); of the 111 patients receiving
chemoradiotherapy, there were 27 relapses and 24 deaths (of which 21 were dis-
ease related). The median follow-up time was 3.2 years. Both treatment groups
were well balanced with respect to most characteristics — gender, race, tumour
size, nodal status, TNM staging (disease stage). Full details of the trial are
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provided by Wee et al. (2005).
The NP01 dataset has been analysed using the competing risks approach to
compute the cumulative incidence function. However, this approach does not
take into account the additional information due to the unique dependent cen-
soring. The competing risks approach would not utilise the information from
the survival times of patients who have suffered relapse, but can still be anal-
ysed for time to death (the upper wedge). Here, we aim to use the model from
Section 3.2 to incorporate this special nature of the data.
In this trial, two endpoints were of interest — time to relapse and time to mor-
tality. Although death was the primary outcome, relapse was also considered
to be an important endpoint because it has been found that a substantial pro-
portion of patients with Stage III or IV endemic NPC relapsed locoregionally
and/or systematically with RT alone. Table 3.4 shows the breakdown of relapse
and deaths according to the compartment model for each treatment group.
Table 3.4: Number of relapses and deaths in each treatment group (data from
Wee et al., 2005).
No. of patients
Event CRT RT Total
Relapse without death 11 9 20
Death without relapse 8 5 13
Relapse with death 16 39 55
Total 35 53 88
We fit the additive risk frailty model, using the Gamma distribution with shape
θ−1 and scale θ. As an initial analysis, we fit only the treatment covariate, with
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the patients receiving CRT as the reference group. Table 3.5 shows the result
of the model fitting. Treatment was significant in the relapse arm and only
marginally significant in the death after relapse arm. The estimate indicates
that the addition of chemotherapy to radiotherapy seems to decrease the hazard
of relapse of an individual by 0.0746 for an individual receiving CRT as compared
to one receiving RT alone. A similar observation can be made for hazard of
death after relapse. The instantaneous risk of death after relapse decreases by
0.353 for an individual receiving CRT as compared to one receiving RT alone.
The estimate of the variance of the frailty parameter was θˆ = 0.00012. This
indicates little relationship between the three arms of the compartment model
for the semi-competing risks data of NP01 under this gamma frailty model.
It can also be observed that under the semi-competing risks setting, the treat-
ment effect is different in the two death arms. For death without relapse, the
addition of chemotherapy resulted in worser survival rates as compared to pa-
tients receiving only RT, although this effect was not significant. In contrast,
patients receiving CRT had better chances of survival from death after relapse
as compared to patients receiving RT and this effect was marginally significant.
Table 3.5: Estimation of treatment effect based on Additive Risk Frailty Model
for Semi-competing Risks (data from Wee et al., 2005).
Relapse Death without Relapse Death after Relapse
Treatment a 0.075 * −0.013 0.353
(0.033) (0.021) (0.205)
Loglikelihood −329.854
Standard errors given in parentheses and * indicates significance at 5% level.
aCRT as reference group
Figure 3.2 shows the survival curves comparing the treatment effect under the
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Figure 3.2: Survival functions comparing treatment effect on time to (from top
to bottom): (a) relapse; (b) death without relapse; and (c) death after relapse
(data fromWee et al., 2005). — gives the survival function for patients receiving
CRT; - - - gives the survival function for patients receiving RT.
3.5 Application to NP01 Clinical Trial 75
above model. The cumulative effect of an additive risk model can be seen over
time. Based on Figure 3.2, the 2- and 3-year disease-free survival rates were
about 75% v 65% and 73% v 58% for locally advanced NPC patients in the CRT
v RT group respectively. As for overall survival rate, we can observe the two
arms of death without relapse and death after relapse. In the death without
relapse arm, there was little treatment effect, but estimation indicates that the
addition of chemotherapy to radiotherapy results in a worse survival rate; the
2- and 3-year survival rate was about 92% v 96% and 90% v 95% for patients in
the CRT v RT groups respectively. In the death after relapse arm, the survival
rates are worse, with the 1- and 2-year survival rate after relapse has occurred
at about 62% v 44% and 36% v 16% for patients in the CRT v RT groups
respectively. As expected, patients who suffer relapse had worser survival rates
as compared to those who died without relapse, in particular, patients who
received RT appear to have less than 50% survival chance if they experience
relapse as compared to patients in the same treatment group who did not suffer
relapse.
We also fit the additive risk frailty model to account not only for treatment,
but also for nodal status (stratifying between N0–2 and N3) and tumour size
(TNM staging, stratifying between Stage 2–3 and 4). Table 3.6 shows the
results of the fitting. The conclusions with regard to statistical significance of
individual covariates are the same as before, even after accounting for the strata
of nodal status and TNM staging. One reason for this observation could be that
the treatment groups were well-balanced with respect to most characteristics
and hence, we would not expect the inclusion of these covariates to affect our
analysis. The frailty variance was estimated at 0.006 (SE=0.022), which implies
an insignificant dependence relationship between the three arms of the relapse-
death model. Figure 3.3 shows the survival curves comparing the treatment
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effect on relapse under the adjusted model. As can be seen, patients with
higher nodal status and TNM staging have lower recurrence-free rates.
Table 3.6: Estimators for Additive Risk Frailty Model for Semi-competing Risks,
accounting for treatment, nodal status and TNM staging (data from Wee et al.,
2005).
Relapse Death without Relapse Death after Relapse
Treatment a 0.071 * −0.001 0.355
(0.033) (0.058) (0.210)
Nodal status b 0.038 −0.009 0.018
(0.056) (0.062) (0.252)
TNM staging c 0.038 0.024 0.027
(0.038) (0.100) (0.275)
Loglikelihood −328.136
Standard errors given in parentheses and * indicates significance at 5% level.
aCRT as reference group
bN0–2 as reference group
cStage 3 as reference group
In both models analysed so far, the frailty parameter seems to indicate a lack
of association between relapse and death. Thus, we consider the restricted
model, which assumes that the two death arms share the same hazard function,
conditional on the frailty, that is, β2 = β3 and λ02 = λ03. Table 3.7 shows the
results of the restricted model evaluating treatment effect only.
The estimates obtained show significant protective effect of CRT as compared to
RT for both the relapse and death outcomes, although the effect in the relapse
arm is only significant at the 10% level. Also, the protective effect increases
in the death arm, as can be seen from the larger value of the estimate. In
addition, the frailty parameter is now estimated at 1.28 (SE=0.335) and is now
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Figure 3.3: Survival functions comparing treatment effect on time to relapse,
stratifying for nodal status and TNM staging: (a) Nodal status N0–2, TNM
Stage 2–3; (b) Nodal status N3, TNM Stage 2–3; (c) Nodal status N0–2, TNM
Stage 4; (d) Nodal status N3; TNM Stage 4 (data from Wee et al., 2005). —
gives the survival function for patients receiving CRT; - - - gives the survival
function for patients receiving RT.
Table 3.7: Estimation of treatment effect based on Restricted Additive Risk
Frailty Model for Semi-Competing Risks (data from Wee et al., 2005).
Relapse Death
Treatment a 0.088 0.106 *
(0.052) (0.035)
Loglikelihood −364.44
Standard errors given in parentheses and * indicates significance at 5% level.
aCRT as reference group
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significant, whereas the estimate under the general (three arms) compartment
model was close to 0 and not significant. This new estimate indicates that there
is an association between relapse and death. The survival rates for relapse and
death can be examined in Figure 3.4. The 2- and 3-year disease-free survival
can be seen from the survival functions for relapse and are estimated at 83% v
73% and 80% v 66% for the CRT v RT groups respectively. The 2- and 3-year
overall survival rates are estimated from the survival functions for death and
are 87% v 75% and 81% v 65% for the CRT v RT groups respectively. These
estimates are close to the ones obtained by Wee et al. (2005).
Figure 3.4: Survival functions comparing treatment effect on: (a) time to relapse
and (b) time to death, for an individual under restricted additive model (data
from Wee et al., 2005). — gives the survival function for patients receiving
CRT; - - - gives the survival function for patients receiving RT.
We also conducted a likelihood ratio test to see if the general model was a better
fit for the data, or if the restricted model was sufficient. The test statistic was
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69.18 and yielded a p-value of <0.001 under the χ2 distribution with 9 degrees
of freedom. This indicates strong evidence against the restricted model, when
we consider our formulation of the general model.
In a similar fashion, we also fit the additive restricted frailty model and ad-
justed for treatment, nodal status and TNM staging. The estimates are given
in Table 3.8. Compared to the restricted model with treatment only, the es-
timates for treatment effect are similar and only the treatment estimates are
marginally significant in this model. The estimate of the frailty parameter
was 2.01 (SE=0.502) and was highly significant, indicating a strong association
betwen relapse and death. A likelihood ratio test was used to compare this
adjusted model against the same adjusted general compartment model fitted
earlier. The test statistic obtained was 46.8 with a p-value <0.001 under the χ2
distribution with 11 degrees of freedom, indicating strong evidence against the
restricted model.
Table 3.8: Estimators for Restricted Additive Risk Frailty Model for Semi-
Competing Risks, accounting for treatment, nodal status and TNM staging
(data from Wee et al., 2005).
Relapse Death
Treatment a 0.134 0.108
(0.070) (0.060)
Nodal status b 0.136 0.065
(0.146) (0.110)
TNM staging c 0.070 0.135
(0.100) (0.097)
Loglikelihood −351.534
Standard errors given in parentheses and * indicates significance at 5% level.
aCRT as reference group
bN0–2 as reference group
cStage 3 as reference group
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3.6 Discussion
In this chapter, we applied additive hazards to the conditional frailty model to
account for covariates, where the frailty term measured the potential relation-
ship between relapse and death times for each individual. The additive hazards
model can provide a complementary analysis to the usual Cox model where the
covariate effect is multiplicative. Simulations indicated that the method works
reasonably well. Further discussion on the methodology is found in Chapter 5.
Application of the conditional additive risk frailty model on the NP01 dataset
utilises more information than the original literature of Wee et al. (2005), which
analysed the data as competing risks. In contrast, our proposed model accounts
for the unique censoring relationship between relapse and death. Results from
the model fitting indicate similar results to Wee et al. (2005) in that the addition
of nodal status and TNM staging as covariates did not yield different estimates
from the model that included treatment only. We also confirmed the findings
that chemotherapy improves the relapse control rate in NPC.
Under the semi-competing risks setting, we obtained further insight on overall
survival as we now examine death as two outcomes - with and without relapse
of NPC. In the trial conducted by Wee et al. (2005), overall 2- and 3-year
survival rates were found to be 85% v 78% and 80% v 65% for CRT and RT
treatment groups respectively. Similar survival rates were also obtained under
the restricted additive fraily model. However, when compared against the gen-
eral model, the restricted model was not sufficient as our likelihood ratio test
indicated.
For the general model, we obtained higher survival rates in our analysis for 2-
and 3-year survival rates for the two treatment groups in the death without
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relapse arm. On the other hand, the death with relapse arm had substantially
lower 2- and 3-year survival rates as compared to Wee et al. (2005). This is
also seen in the estimates obtained. One possible reason for the difference could
be the unique relationship between death and relapse and by accounting for
this relationship as we have done in our model, it reveals the distinct difference
between the two death outcomes rather than examining all the deaths for overall
survival, while examining death as a single outcome without accounting for
relapse might cause the two effects to cancel each other out.
This dataset was analysed in Lim’s (2010) thesis, which considered a parametric
proportional hazards model with a Weibull baseline and Gamma shared frailty.
Only treatment effect was accounted for and her model did not indicate signifi-
cant effect of adjuvant chemotherapy, although the observations made from the
estimates alone (regardless of significance) showed the same conclusion as the
analysis done in this chapter.
Xu et al. (2010) also analysed the same dataset, but considered the proportional
hazards model with shared frailty and nonparametric baseline hazards. Other
differences in our analyses and that of Xu et al. include different covariates
used in adjustment. This chapter adjusts for nodal status (N0–2 v N3) and
TNM staging (Stage 3 v Stage 4), while the latter adjusts for tumour size and
nodal status and accounts for them as categorical variables with 4 levels each.
The observations on treatment effect are similar in both analyses — patients
in the CRT group had significantly increased chances of disease-free survival
and overall survival after relapse, but experienced decreased chances of overall
survival without relapse, although the last effect was not significant. In addition,
the estimate of the frailty parameter was found to be highly significant in their
analysis, but was not in this chapter.
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The estimated frailty parameter under the general model was found to be a
small and non-significant value. A possible reason for this is that the general
compartment model allows the hazards in the death arms to differ. The frailty
in the restricted model captures the difference of hazards with and without
relapse since we assume β2 = β3 and λ02 = λ03. Thus intuitively, we can expect
the frailty variance to be smaller than that in the reduced model. In addition,
we have assumed the frailty to follow the Gamma distribution. In practice, this
might not be true, resulting in an inaccurate estimate for the frailty parameter.







The focus of this thesis thus far has been on the additive risk model. We now ex-
tend the additive risk frailty model to the more general additive-multiplicative
hazard models for the analysis of semi-competing risks data. For univariate
survival data, the general class of additive-multiplicative model has been stud-
ied. The additive hazards and multiplicative hazards models postulate different
relationships between the covariates and the hazard function and the choice be-
tween additive or multiplicative hazards can be an empirical decision or based
on physical logic. The general class of additive-multiplicative models has the
flexibility of allowing some covariate effects to be additive while letting others
be multiplicative or allowing certain covariates to have both the additive and
multiplicative effects.
A simple additive-multiplicative model was first analysed by Andersen and
Værth (1989), which looked at relative and excess mortality in comparison to a
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known population mortality, λ∗(t). Their model was given as
λ(t) = α(t) + β(t)λ∗(t),
where α(t) and β(t) measured the excess and relative risk respectively, but did
not account for covariate effects. The proportional excess hazards model was
also examined by Sasieni (1996). Lin and Ying (1995) studied the class of
models given by
λ(t|W,X) = g{αT0W (t)}+ λ0(t)h{βT0 X(t)},
where g and h are known link functions, W and X are possibly time-varying
covariates and λ0 is an unspecified baseline hazard under g = 0 and h = 1. It
is easy to see that such a class of models encompasses both the additive model
(g(x) = x, h = 1) and the Cox model (g = 0, h(x) = ex). Under this model, all
covariate effects are fixed and not time-varying.
Martinussen and Scheike (2002) and Scheike and Zhang (2002) suggested two
different additive-multiplicative models with time-varying covariate effects. In
the former, Martinussen and Scheike (2002) examined a model similar to Lin
and Ying (1995) with g as the identity link and h as the exponential link, but
they allowed α0 to vary with time while keeping β0 as time-invariant. Scheike
and Zhang (2002) considered a variation from the above models and extended
the Cox model by allowing the baseline hazard to depend on covariates through
the additive Aalen model. Their model was given as
λ(t|W,X) = (α0(t)TW (t))λ0(t)h{βT0 X(t)}.
In this chapter, we propose to extend the general additive-multiplicative model
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to the semi-competing risks setting discussed in Chapter 3. Conditional on the
frailty term, the hazard function is an additive-multiplicative function following
that of Lin and Ying (1995) with g(x) = x and h(x) = ex. Similar to Chapter
3, we model the baseline hazard functions via cubic B-splines with fixed knots.
4.2 Proposed Additive-Multiplicative Model
4.2.1 Additive-Multiplicative Model
Using the same notation as in Section 3.2 for the failure times, we have the
hazard functions for the i-th individual as:
λ1(t|Ti2 ≥ t, γi,Wi,Zi) = γi(λ01(t) exp(αT1Wi(t)) + βT1Zi(t)),
λ2(t|Ti1 ≥ t, γi,Wi,Zi) = γi(λ02(t) exp(αT2Wi(t)) + βT2Zi(t)),
λ3(t|Ti1 ≤ t, γi,Wi,Zi) = γi(λ03(t) exp(αT3Wi(t)) + βT3Zi(t)), (4.1)
where W and Z are covariate vectors with corresponding vectors of unknown
regression parameters, α and β, and as in Chapter 3, γi is the frailty term
for each individual and assumed to be independent and identically distributed
from the Gamma distribution with shape θ−1 and scale θ. Again, the Gamma
distribution is assumed for mathematical convenience.
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4.2.2 Estimation for Additive-Multiplicative Model
Similar to Chapter 3, we propose to use cubic B-splines to estimate the three
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where λ0m(t) is estimated by Equation (3.2) and Λ0m(t) (m = 1, 2, 3) is esti-
mated by Equation (3.4).
This loglikelihood function can be maximised over the finite dimensional space
for the parameters ψ = {αT1 ,αT2 ,αT3 ,βT1 ,βT2 ,βT3 , θ, c11, . . . , c1J , c21, . . . , c2J , c31, .
.., c3J}.
4.3 Theoretical Properties
In this section we use the assumptions listed in Section 3.3. The proofs of
consistency and asymptotic normality are similar to Chapter 3 and follow in
outline to that of Murphy (1995) and Xue et al. (2004) and are not given here.
Let ψ0 be the true values of the parameters.
Theorem 4.3.1. (Consistency). If the conditions 1–3 in Section 3.3 hold, then
ψˆ
P−→ ψ0.
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Theorem 4.3.2. (Asymptotic normality). If the conditions 1–3 in Section 3.3
hold, then
√
n(αˆ − α0, βˆ − β0, θˆ − θ0) is asymptotically normal, where α =
(α1,α2,α3) and β = (β1,β2,β3).
4.4 Simulation Results for Extended Model
For simplicity, we consider the reduced model where λ2 = λ3, that is, λ02 = λ03
and β2 = β3.
4.4.1 Data Generation of Semi-Competing Risks under
Extended Model
The algorithm to generate survival times T1 and T2 and the observed data is as
follows:
1. Generate T1 and T2 from distributions based on λ1 and λ2 respectively.
That is, T1 is generated from a distribution F1, whose hazard function is
λ1. T2 is generated in a similar fashion.
2. If T1 > T2, generate T* from distribution with hazard function λ2 and set
T2 = T1 + T ∗.
3. Generate censoring time, C, from Uniform[0,a] for some a > 0.
4. If T2 < C, set δ2 = 1 and Y = min(T2, C).
5. If T1 < min(T2, C), set δ1 = 1 and X = min(T1, Y ).
The observed data for each sample of size n is then {Xi, δ1i, Yi, δ2i, Zi}ni=1.
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4.4.2 Simulation Results for Additive-Multiplicative Haz-
ards on Semi-Competing Risks
For the reduced model, we consider the case of a single discrete covariate Z
generated from the Bernoulli(0.5) distribution for the additive component and
a single continuous covariate W from the standard Normal distribution for the
multiplicative component. Simulations were conducted for a sample size of 400,
and at two degrees of censoring, 10% and 30%. We fix the baseline hazard
to be from the exponential distribution with mean 1. Two sets of true val-
ues are considered for the regression coefficients of the respective hazards —
(α1, α2, β1, β2) = (0, 0, 1, 1) and (α1, α2, β1, β2) = (−0.5, 0, 0.5, 1); and we vary
the true values of θ for the Gamma frailty distribution — 0.5, 0.95, 1.5.
We generate 1000 simulations for each combination of censoring, regression co-
efficients and θ. Tables 4.1, 4.2, 4.3 show the results and for each parameter
combination give: (i) the Estimate (Est),the average of 1000 estimates; (ii) the
Empirical Standard Error (EmpSE), the standard deviation of the 1000 esti-
mators; (iii) the Model Standard Error (ModSE), the average of 1000 standard
error estimators, using the information matrix.
The results show that the method works reasonably well, with small biases of
about 0.1 or less. Empirical and estimated variances based on the information
matrix were relatively similar. Also, larger values of coefficients result in larger
biases and standard errors. However, they give smaller absolute biases per unit
of standard error. The exception is θˆ, which has a mostly constant value of 0.5
of absolute bias per unit of standard error. Larger values of θ resulted in larger
standard error estimates for all parameters.
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Table 4.1: Estimators for Additive-Multiplicative Risk Frailty Model for Re-
duced Model of Semi-Competing Risks Data with single W from standard Nor-
mal and single Z from Bernoulli(0.5) and θ = 0.5, with 10% and 30% censoring
and varying α and β.
(α1, α2, β1, β2) = (0, 0, 1, 1)
[0,a] Cens Est EmpSE ModSE
[0, 6.6] 10% α1 0.0022 0.137 0.127
α2 0.0049 0.152 0.152
β1 1.0997 0.346 0.327
β2 1.1000 0.279 0.272
θ 0.5735 0.130 0.125
[0, 1.7] 30% α1 0.0050 0.139 0.136
α2 −0.0015 0.164 0.157
β1 1.1195 0.366 0.369
β2 1.1192 0.303 0.306
θ 0.5948 0.176 0.182
(α1, α2, β1, β2) = (−0.5, 0, 0.5, 1)
[0,a] Cens Est EmpSE ModSE
[0, 6.6] 10% α1 −0.5137 0.125 0.126
α2 −0.0014 0.157 0.155
β1 0.5543 0.251 0.254
β2 1.1100 0.277 0.277
θ 0.5779 0.133 0.133
[0, 1.7] 30% α1 −0.5152 0.136 0.135
α2 0.0006 0.147 0.157
β1 0.5566 0.275 0.284
β2 1.1073 0.305 0.308
θ 0.5794 0.173 0.191
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Table 4.2: Estimators for Additive-Multiplicative Risk Frailty Model for Re-
duced Model of Semi-Competing Risks Data with single W from standard Nor-
mal and single Z from Bernoulli(0.5) and θ = 0.95, with 10% and 30% censoring
and varying α and β.
(α1, α2, β1, β2) = (0, 0, 1, 1)
[0,a] Cens Est EmpSE ModSE
[0, 12] 10% α1 −0.0015 0.172 0.158
α2 0.0026 0.204 0.191
β1 1.1135 0.374 0.367
β2 1.1134 0.321 0.317
θ 1.0382 0.164 0.165
[0, 2.4] 30% α1 −0.0032 0.161 0.154
α2 −0.0054 0.168 0.179
β1 1.0984 0.387 0.387
β2 1.1017 0.339 0.334
θ 1.0287 0.201 0.214
(α1, α2, β1, β2) = (−0.5, 0, 0.5, 1)
[0,a] Cens Est EmpSE ModSE
[0, 12] 10% α1 −0.5143 0.160 0.153
α2 0.0064 0.196 0.195
β1 0.5640 0.282 0.285
β2 1.1218 0.329 0.323
θ 1.0440 0.173 0.173
[0, 2.4] 30% α1 −0.5201 0.167 0.153
α2 0.0007 0.201 0.189
β1 0.5852 0.298 0.311
β2 1.1376 0.345 0.346
θ 1.0654 0.221 0.230
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Table 4.3: Estimators for Additive-Multiplicative Risk Frailty Model for Re-
duced Model of Semi-Competing Risks Data with single W from standard Nor-
mal and single Z from Bernoulli(0.5) and θ = 1.5, with 10% and 30% censoring
and varying α and β.
(α1, α2, β1, β2) = (0, 0, 1, 1)
[0,a] Cens Est EmpSE ModSE
[0, 30] 10% α1 0.0065 0.211 0.217
α2 0.0128 0.260 0.265
β1 1.1072 0.398 0.408
β2 1.1050 0.367 0.363
θ 1.6045 0.209 0.217
[0, 3.9] 30% α1 0.0054 0.190 0.185
α2 0.0060 0.220 0.220
β1 1.1193 0.422 0.431
β2 1.1091 0.371 0.375
θ 1.6100 0.254 0.259
(α1, α2, β1, β2) = (−0.5, 0, 0.5, 1)
[0,a] Cens Est EmpSE ModSE
[0, 30] 10% α1 −0.5120 0.204 0.214
α2 0.0009 0.266 0.283
β1 0.6033 0.307 0.324
β2 1.1485 0.380 0.374
θ 1.6199 0.223 0.228
[0, 3.9] 30% α1 −0.5123 0.182 0.181
α2 0.0143 0.231 0.229
β1 0.5892 0.319 0.337
β2 1.1248 0.384 0.381
θ 1.6427 0.275 0.276
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4.5 Application to NP01 Dataset
We apply this general additive-multiplicative frailty model to the NP01 dataset
described in Section 3.5. In the analysis of the previous chapter, the additive
risk frailty model that analysed treatment effect while adjusting for nodal sta-
tus and TNM staging showed little improvement over the model that analysed
treatment effect alone. Hence, we apply the reduced model used in the simula-
tions and adjust for the same covariates. We imposed a multiplicative effect on
the treatment covariate and additive effects on nodal status and TNM staging.
This is to compare our results obtained with those of Xu et al. (2010) and the
thesis written by Lim (2010), where both analysed the treatment covariate as
having a multiplicative effect. Table 4.4 shows the results of the modelling.
Table 4.4: Estimators for Additive-Multiplicative Risk Frailty Model for Semi-
Competing Risks, accounting for treatment, nodal status and TNM staging
(data from Wee et al., 2005).
Relapse Death
Multiplicative component
Treatment a 1.581 * 2.243 *
(0.513) (1.023)
Additive component
Nodal status b 0.343 * 0.103 *
(0.169) (0.048)
TNM staging c −0.190 * 0.063
(0.022) (0.084)
Standard errors given in parentheses and * indicates significance at 5% level.
aCRT as reference group
bN0–2 as reference group
cStage 3 as reference group
The association between relapse and death was measured through the frailty
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and the variance of the assumed Gamma distribution was estimated as 6.205
(SE=1.325), which is highly significant. This indicates a strong association
between relapse and death.
After accounting for the association in the model, the covariate effects are now
significant. Patients in the CRT group fared better than the RT group in
both the relapse arm and death arm, with hazard ratios e−1.581 = 0.206 and
e−2.243 = 0.106 respectively. This confirms the significant survival benefit of
CRT treatment over the RT treatment. In addition, the adjusted variables also
have a significant effect on survival, in terms of excess risk. Patients with higher
nodal status have a higher risk of relapse and of death. As for TNM staging,
the effect differs in the relapse and death arm. Patients with a higher TNM
Stage have a lower risk of relapse, but higher risk of death. However, the effect
of TNM staging on death is not significant. In contrast, the estimated effects
of the adjusted variables were not significant in Chapter 3.
Figures 4.1 and 4.2 show the curves for disease-free survival (time to relapse) and
overall survival (time to death). In contrast to the additive model where the ef-
fect on survival is cumulative and increases over time, the additive-multiplicative
model has effects which do not necessarily increase over time, as can be seen in
the graphs. Even after accounting for nodal status and TNM staging, patients
in the CRT group are observed to have better survival chances with regard to
both death and relapse. In all combinations of nodal status and TNM stag-
ing, the difference between the survival chances of the CRT and RT groups
becomes constant after about 2 years. Thus, the effect of adding chemotherapy
to radiotherapy is largely seen within the first 2 years of randomisation.
The comparison of survival rates also varied for patients in different nodal status
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Figure 4.1: Survival functions comparing treatment effect on time to relapse for
an individual under additive-multiplicative reduced model, stratifying for nodal
status and TNM staging: (a) Nodal status N0–2, TNM Stage 2–3; (b) Nodal
status N3, TNM Stage 2–3; (c) Nodal status N0–2, TNM Stage 4; (d) Nodal
status N3; TNM Stage 4 (data from Wee et al., 2005). — gives the survival
function for patients receiving CRT; - - - gives the survival function for patients
receiving RT.
groups. For patients with nodal status N0–N2, the 2-year disease-free survival
rate was about 85% for the CRT group, while the rate were about 60% for the
RT group. For patients with nodal status N3, the 2-year disease-free survival
rate was about 73% for the CRT group compared to 60% for the RT group. The
same analysis can be made for overall survival rates. For patients with nodal
status N0–N2, the 2-year overall survival rate was about 90% for the CRT group
and 78% for the RT group. Patients with nodal status N3 had estimated 2-year
survival rates of 83% if they were in the CRT group and 60% if they were in
the RT group.
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Figure 4.2: Survival functions comparing treatment effect on time to death for
an individual under additive-multiplicative reduced model, stratifying for nodal
status and TNM staging: (a) Nodal status N0–2, TNM Stage 2–3; (b) Nodal
status N3, TNM Stage 2–3; (c) Nodal status N0–2, TNM Stage 4; (d) Nodal
status N3; TNM Stage 4 (data from Wee et al., 2005). — gives the survival
function for patients receiving CRT; - - - gives the survival function for patients
receiving RT.
From the graphs, we can also see that within the treatment groups, patients
were more likely to suffer a relapse than death.
4.6 Discussion
In this chapter, we generalise the frailty model for semi-competing risks data to
include both the additive and multiplicative components. Simulations on the
reduced model show the method works well for moderate sample sizes. The
estimation for the multiplicative component seems to fare better than the esti-
mation for the additive coefficients. This could be due to the fact that there is no
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constraint on the regression coefficients for the multiplicative component while
the additive coefficients need to be constrained such that the hazards are non-
negative hazards, ie., that λm(t) ≥ 0 for m = 1, 2, 3. Application to the NPC
dataset provides insight for the covariate effects, where the effects of treatment,
nodal status and TNM staging are all significant. Under the reduced compart-
ment model, adjuvant chemotherapy is observed to have significant protective
effect, although the estimated effect appears to be implausibly large. This could
be due to the restrictive assumptions of the model made in this chapter. In
contrast, the estimate of the treatment effect under the restricted proportional
hazards model proposed by Lim (2010) is smaller but not significant, while the
estimates of Xu et al. (2010) under their restricted model produced a hazard
ratio of about 0.345 when comparing CRT to RT and accounting for tumour
size and nodal status. The estimate of the frailty parameter obtained in this
chapter (θˆ = 6.2 with SE=1.3) is similar to the estimate of 7.0 obtained by
Xu et al. (2010), indicating the strong relationship between relapse and death.
Further work on the dataset could look into additive-multiplicative effects for
different combinations of the covariates to see which gives the best fit. Models
with less restrictive assumptions can also be explored to see if more plausible
estimates of multiplicative treatment effect can be obtained. Model checking






In biomedical studies, it is often of interest to evaluate drug efficacy in clinical
trials in diseases. Although death is an important endpoint, it is also essential
to study intermediate events like disease relapse, as they can provide additional
information. This area of semi-competing risks has often been analysed based
on a competing risks framework, due to the lack of an appropriate methodology.
Methods for analysing such data have been proposed in the existing literature
and were discussed in Chapter 1. These methods involve the use of copula
models and assumptions on the existence of the marginal distribution for the
time to the non-terminal event. In contrast, our proposed frailty model based
on additive hazards does not make such assumptions and our analysis is focused
only on the observable range of the data.
With the frailty model, covariate effects can be explicitly modelled and have a
direct interpretation, as compared to the copula models. While the proportional
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hazards model is the most commonly used regression model in univariate and
multivariate survival analysis, we propose the additive risk model as a comple-
mentary measure. As mentioned in Chapter 1, it may make more biological
sense in some cases to consider excess risk of a covariate instead of its relative
risk. For example, the latent period for the risk of cancer following exposure to
low doses of ionizing radiation can be better understood in terms of an additive
risk model (Huffer and McKeague, 1991). Buckley (1984) shows that assuming
a multiplicative model for analysis can have very misleading results when the
data is from an additive model.
As such, Chapter 2 looked at the setting of competing risks and applied the ad-
ditive risk model to the two widely-applied approaches for handling competing
risks data — cause-specific hazards and subdistribution hazards respectively.
We also proposed an additive risk model with time-varying coefficients for the
subdistribution hazards model due to model limitations of the model with con-
stant coefficients. Although there was a lack of fit in the subdistribution hazards
model when applied to the prostate cancer dataset, this could be due to the
specification of the time-varying form. If the time-varying form was correctly
specified, then the proposed model would work well in practical settings, as
demonstrated in the simulations. Other time-varying forms we could consider
include α(t) = β/t.
For the additive risk frailty model in Chapter 3, while we can allow the baseline
hazard to be estimated nonparametrically, we propose the use of spline approx-
imations to model the baseline hazard to reduce the complexity of the model.
Splines have been widely used in modelling and are known for their flexibility.
Our simulation studies indicate that the use of cubic B-splines to approximate
the baseline hazard functions do not affect the estimation of the regression coef-
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ficients and are flexible enough to estimate the continuous form of the unknown
baselines.
When fitting the additive hazards model, it needs to be ensured that the overall
hazard is non-negative. One way to account for this constraint would be to
reparameterize βTZ to become exp(βTZ), but this makes interpretation of the
coefficients less straightforward. Hence, we choose to retain the original form
of the additive risk model and work with contrained optimization. There are
many packages in statistical software readily available to cope with constrained
optimization. Also note that the contraints here are not on specific parameters
but only on the overall hazard.
We applied our proposed model in Chapter 3 to analyse a real dataset of patients
with endemic nasopharyngeal cancer. Results from the restricted model show
similar observations as the original clinical paper (Wee et al., 2005). Fitting
of the additive risk frailty hazards to the general compartment model showed
significant protective effect of CRT as compared to RT in the relapse and death
after relapse arms. However, patients in the CRT group experienced an increase
in risk of death without relapse as compared to those in the RT group. However,
the frailty variance was found to be small and close to 0, indicating a lack of
association between relapse and death.
In Chapter 4, we extended the model to the general additive-multiplicative
frailty model to include the conditional proportional hazards and additive haz-
ards as special cases. Simulations on the reduced model indicate reasonable
performance for moderate sample sizes. Analysis on a real dataset of patients
with endemic NPC using the restricted additive-multiplicative frailty model
showed significant protective effect of CRT as compared to RT in both the
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relapse and death outcomes. The estimated frailty variance also indicated a
significant relationship between relapse and death.
5.2 Further Work
This thesis has attempted to shed some light on the modelling of semi-competing
risks data through the use of shared frailties to model the dependence between
the terminal and non-terminal events and an additive risk model to capture
covariate effects. Further work in this area could include:
1. The consideration of other frailty distributions, such as the log-normal
or positive stable distributions. The positive stable distribution has been
shown to preserve proportionality of the hazards in the marginal distri-
bution (Hougaard, 1986b). It would be worth investigating how these
distributions behave in an additive risk setting and to analyse their prop-
erties.
2. Model-checking procedures to analyse goodness-of-fit of the restricted and
general compartment models and also for model selection. Procedures
could also be developed to check frailty assumptions.
3. Extension of spline approximations to tensor splines, to account for the
bivariate nature of the terminal and non-terminal event times observed in
the death after relapse arm of the compartment model. This would require
a more in-depth study of the nature of splines, their uses and theoretical
properties.
4. Extension of the proposed additive and additive-multiplicative models to
accommodate data of other censoring structures, such as bivariate data,
multivariate data and recurrent failure time data.
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